Trial Outcomes & Findings for Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916 (NCT NCT02064387)
NCT ID: NCT02064387
Last Updated: 2020-08-11
Results Overview
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, other medical events according to medical or scientific judgement and all events of possible study treatment-induced liver injury with hyperbilirubinemia. Part 1 Population comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916. SAEs and common (\>=5%) non-SAEs is presented.
Recruitment status
COMPLETED
Study phase
PHASE1
Target enrollment
79 participants
Primary outcome timeframe
Up to 23.5 months (maximum duration of follow-up from first dose to last contact or death)
Results posted on
2020-08-11
Participant Flow
This is a Phase1 study of antibody drug conjugate GSK2857916 in participants with relapsed/refractory multiple myeloma(MM) or non-hodgkin's lymphoma (NHL).The study was conducted in 2 parts-Part1(dose escalation) and Part2(dose expansion).The starting dose in Part1 was 0.03mg/kg GSK2857916 given once every three weeks; 1cycle=21 days for 16cycles.
A total of 79 participants were enrolled (38 participants in Part-1 and 41 participants in Part-2).
Participant milestones
| Measure |
Part 1: GSK2857916 0.03 mg/kg
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 2: GSK2857916 3.40 mg/kg (MM)
Participants with multiple myeloma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle=21 days).
|
Part 2: GSK2857916 3.40 mg/kg (NHL)
Participants with non-hodgkin's lymphoma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 36 cycles (1 cycle=21 days)
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Part 1 Max 23.5 Months Followup Duration
STARTED
|
1
|
1
|
4
|
4
|
4
|
3
|
4
|
8
|
3
|
6
|
0
|
0
|
|
Part 1 Max 23.5 Months Followup Duration
COMPLETED
|
1
|
1
|
4
|
4
|
4
|
3
|
4
|
6
|
2
|
5
|
0
|
0
|
|
Part 1 Max 23.5 Months Followup Duration
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
1
|
1
|
0
|
0
|
|
Part 2 Max 35 Months Followup Duration
STARTED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
35
|
6
|
|
Part 2 Max 35 Months Followup Duration
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
29
|
3
|
|
Part 2 Max 35 Months Followup Duration
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
6
|
3
|
Reasons for withdrawal
| Measure |
Part 1: GSK2857916 0.03 mg/kg
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 2: GSK2857916 3.40 mg/kg (MM)
Participants with multiple myeloma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle=21 days).
|
Part 2: GSK2857916 3.40 mg/kg (NHL)
Participants with non-hodgkin's lymphoma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 36 cycles (1 cycle=21 days)
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Part 1 Max 23.5 Months Followup Duration
Death
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
0
|
0
|
|
Part 1 Max 23.5 Months Followup Duration
Lost to Follow-up
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
|
Part 1 Max 23.5 Months Followup Duration
Withdrawal by Subject
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
Part 2 Max 35 Months Followup Duration
Death
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
3
|
|
Part 2 Max 35 Months Followup Duration
Withdrawal by Subject
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
Baseline Characteristics
Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916
Baseline characteristics by cohort
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=1 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
n=1 Participants
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=4 Participants
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=4 Participants
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=4 Participants
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=3 Participants
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=4 Participants
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
n=8 Participants
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=3 Participants
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
n=6 Participants
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 2: GSK2857916 3.40 mg/kg (MM)
n=35 Participants
Participants with multiple myeloma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle=21 days).
|
Part 2: GSK2857916 3.40 mg/kg (NHL)
n=6 Participants
Participants with non-hodgkin's lymphoma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 36 cycles (1 cycle=21 days)
|
Total
n=79 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Continuous
|
49.0 years
STANDARD_DEVIATION NA • n=93 Participants
|
71.0 years
STANDARD_DEVIATION NA • n=4 Participants
|
56.5 years
STANDARD_DEVIATION 3.32 • n=27 Participants
|
58.5 years
STANDARD_DEVIATION 8.35 • n=483 Participants
|
60.0 years
STANDARD_DEVIATION 10.89 • n=36 Participants
|
58.7 years
STANDARD_DEVIATION 13.05 • n=10 Participants
|
65.3 years
STANDARD_DEVIATION 4.79 • n=115 Participants
|
62.6 years
STANDARD_DEVIATION 11.04 • n=40 Participants
|
48.0 years
STANDARD_DEVIATION 8.19 • n=8 Participants
|
54.8 years
STANDARD_DEVIATION 10.11 • n=62 Participants
|
60.5 years
STANDARD_DEVIATION 7.93 • n=95 Participants
|
60.2 years
STANDARD_DEVIATION 9.81 • n=129 Participants
|
59.6 years
STANDARD_DEVIATION 8.90 • n=36 Participants
|
|
Sex: Female, Male
Female
|
1 Participants
n=93 Participants
|
0 Participants
n=4 Participants
|
3 Participants
n=27 Participants
|
2 Participants
n=483 Participants
|
2 Participants
n=36 Participants
|
1 Participants
n=10 Participants
|
2 Participants
n=115 Participants
|
5 Participants
n=40 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=62 Participants
|
18 Participants
n=95 Participants
|
3 Participants
n=129 Participants
|
39 Participants
n=36 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=93 Participants
|
1 Participants
n=4 Participants
|
1 Participants
n=27 Participants
|
2 Participants
n=483 Participants
|
2 Participants
n=36 Participants
|
2 Participants
n=10 Participants
|
2 Participants
n=115 Participants
|
3 Participants
n=40 Participants
|
2 Participants
n=8 Participants
|
5 Participants
n=62 Participants
|
17 Participants
n=95 Participants
|
3 Participants
n=129 Participants
|
40 Participants
n=36 Participants
|
|
Race/Ethnicity, Customized
Race · Black or African American
|
0 Participants
n=93 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=27 Participants
|
1 Participants
n=483 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
4 Participants
n=40 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=62 Participants
|
5 Participants
n=95 Participants
|
0 Participants
n=129 Participants
|
10 Participants
n=36 Participants
|
|
Race/Ethnicity, Customized
Race · Arabic/North African Heritage
|
0 Participants
n=93 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=483 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=10 Participants
|
1 Participants
n=115 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=62 Participants
|
0 Participants
n=95 Participants
|
0 Participants
n=129 Participants
|
2 Participants
n=36 Participants
|
|
Race/Ethnicity, Customized
Race · White/Caucasian/European Heritage
|
1 Participants
n=93 Participants
|
1 Participants
n=4 Participants
|
4 Participants
n=27 Participants
|
3 Participants
n=483 Participants
|
4 Participants
n=36 Participants
|
3 Participants
n=10 Participants
|
3 Participants
n=115 Participants
|
4 Participants
n=40 Participants
|
3 Participants
n=8 Participants
|
5 Participants
n=62 Participants
|
28 Participants
n=95 Participants
|
6 Participants
n=129 Participants
|
65 Participants
n=36 Participants
|
|
Race/Ethnicity, Customized
Race · Japanese Heritage
|
0 Participants
n=93 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=483 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=62 Participants
|
1 Participants
n=95 Participants
|
0 Participants
n=129 Participants
|
1 Participants
n=36 Participants
|
|
Race/Ethnicity, Customized
Race · South East Asian Heritage
|
0 Participants
n=93 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=483 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=62 Participants
|
1 Participants
n=95 Participants
|
0 Participants
n=129 Participants
|
1 Participants
n=36 Participants
|
PRIMARY outcome
Timeframe: Up to 23.5 months (maximum duration of follow-up from first dose to last contact or death)Population: Part 1 Population
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, other medical events according to medical or scientific judgement and all events of possible study treatment-induced liver injury with hyperbilirubinemia. Part 1 Population comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916. SAEs and common (\>=5%) non-SAEs is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=1 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
n=1 Participants
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=4 Participants
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=4 Participants
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=4 Participants
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=3 Participants
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=4 Participants
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
n=8 Participants
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=3 Participants
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
n=6 Participants
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Serious Adverse Events (SAEs) and Common (>=5%) Non-serious Adverse Events- Part 1
Common non-SAE
|
1 Participants
|
1 Participants
|
4 Participants
|
4 Participants
|
3 Participants
|
3 Participants
|
4 Participants
|
8 Participants
|
3 Participants
|
6 Participants
|
|
Number of Participants With Serious Adverse Events (SAEs) and Common (>=5%) Non-serious Adverse Events- Part 1
Any SAE
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
4 Participants
|
1 Participants
|
3 Participants
|
PRIMARY outcome
Timeframe: Up to 35 months (maximum duration of follow-up from first dose to last contact or death)Population: Part 2 MM Population
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, other medical events according to medical or scientific judgement and all events of possible study treatment-induced liver injury with hyperbilirubinemia. Part 2 MM Population comprised of all Part 2 MM participants who received at least one dose of GSK2857916. SAEs and common (\>=5%) non-SAEs is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=35 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With SAEs and Common (>=5%) Non-serious Adverse Events- Part 2 (MM)
Common non-SAE
|
35 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With SAEs and Common (>=5%) Non-serious Adverse Events- Part 2 (MM)
Any SAE
|
17 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)Population: Part 2 NHL Population
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, other medical events according to medical or scientific judgement and all events of possible study treatment-induced liver injury with hyperbilirubinemia. Part 2 NHL Population comprised of all Part 2 NHL participants who received at least one dose of GSK2857916. SAEs and common (\>=5%) non-SAEs is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=6 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With SAEs and Common (>=5%) Non-serious Adverse Events- Part 2 (NHL)
Common non-SAE
|
6 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With SAEs and Common (>=5%) Non-serious Adverse Events- Part 2 (NHL)
Any SAE
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Up to Day 21 (from first dose)Population: DLT Evaluable Population(pop) in Part 1 comprised of All Treated Pop (participants who received at least 1 dose of study treatment) and who received a complete infusion in cycle 1 (once every 3 weeks dosing). Any Part 1 participant in the"All Treated" pop who experiences a DLT, will also be included in the DLT evaluable pop regardless of exposure.
An event was considered a DLT if it occurred within the first 21 days of treatment, and met one of the following criteria:albuminuria\>=2000mgper24 hour which has been confirmed by repeat test at least7 days apart and is not considered to be related to disease progression, Grade4 neutropenia (without fever) lasting\>=7 days, febrile neutropenia lasting\>=72 hours, Grade\>=3 thrombocytopenia associated with bleeding where estimated blood loss is\>10 milliliter orGrade4 thrombocytopenia lasting\>7 days and not responding to platelet transfusions, anyGrade3 or greaternon-hematologic toxicity as described in Common National Cancer Institute-Terminology Criteria for Adverse Events version4.0 with the exception of the following Grade3 events that can be controlled within48 hours with routine supportive measures and clinically asymptomatic electrolyte abnormalities which can be corrected within48 hours and liver toxicity meeting pre-specified GSK liver stopping criteria.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=1 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
n=1 Participants
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=4 Participants
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=4 Participants
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=4 Participants
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=3 Participants
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=4 Participants
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
n=8 Participants
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=3 Participants
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
n=6 Participants
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Dose-limiting Toxicities (DLTs) During the Determinative Period- Part 1
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)Population: Part 1 Population
Vital signs included systolic blood pressure (SBP), diastolic blood pressure (DBP), temperature (Temp) and heart rate (HR). SBP and DBP were graded using National Cancer Institute-Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0. For SBP: Grade 0-\<120 millimeters of mercury\[mmHg\], 120-139 mmHg\[Grade 1\], 140-159 mmHg\[Grade 2\], \>=160 mmHg\[Grade 3\]); For DBP: \<80 mmHg \[Grade 0\], 80-89\[Grade 1\], 90-99\[Grade 2\], \>=100 mmHg\[Grade 3\]). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=1 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
n=1 Participants
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=4 Participants
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=4 Participants
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=4 Participants
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=3 Participants
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=4 Participants
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
n=8 Participants
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=3 Participants
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
n=6 Participants
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 1
DBP, any grade increase
|
0 Participants
|
1 Participants
|
2 Participants
|
1 Participants
|
2 Participants
|
3 Participants
|
3 Participants
|
5 Participants
|
3 Participants
|
4 Participants
|
|
Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 1
SBP, any grade increase
|
0 Participants
|
1 Participants
|
2 Participants
|
2 Participants
|
3 Participants
|
1 Participants
|
3 Participants
|
7 Participants
|
2 Participants
|
5 Participants
|
PRIMARY outcome
Timeframe: Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)Population: Part 2 MM Population
Vital signs included SBP, DBP, Temp and HR. SBP and DBP were graded using NCI CTCAE version 4.0. For SBP: Grade 0-\<120 mmHg, 120-139 mmHg\[Grade 1\], 140-159 mmHg\[Grade 2\], \>=160 mmHg\[Grade 3\]); For DBP: \<80 mmHg \[Grade 0\], 80-89\[Grade 1\], 90-99\[Grade 2\], \>=100 mmHg\[Grade 3\]). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=35 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 2 (MM)
DBP, any grade increase
|
30 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 2 (MM)
SBP, any grade increase
|
31 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)Population: Part 2 NHL Population
Vital signs included SBP, DBP, Temp and HR. SBP and DBP were graded using NCI CTCAE version 4.0. For SBP: Grade 0-\<120 mmHg, 120-139 mmHg \[Grade 1\], 140-159 mmHg\[Grade 2\], \>=160 mmHg \[Grade 3\]); For DBP: \<80 mmHg \[Grade 0\], 80-89\[Grade 1\], 90-99\[Grade 2\], \>=100 mmHg\[Grade 3\]). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=6 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 2 (NHL)
DBP, any grade increase
|
5 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 2 (NHL)
SBP, any grade increase
|
5 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)Population: Part 1 Population
The following criteria was used to flag vital signs of potential clinical importance: change from Baseline in heart rate (decrease to \<60 beats per minute \[bpm\] and increase to \>100 bpm) and change in temperature from Baseline (increase to \>=38 or decrease to \<=35 degrees celsius). Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=1 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
n=1 Participants
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=4 Participants
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=4 Participants
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=4 Participants
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=3 Participants
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=4 Participants
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
n=8 Participants
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=3 Participants
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
n=6 Participants
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 1
HR, decrease to <60
|
0 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
4 Participants
|
1 Participants
|
3 Participants
|
|
Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 1
HR, change to normal or no change
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
3 Participants
|
1 Participants
|
1 Participants
|
|
Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 1
HR, increase to >100
|
1 Participants
|
1 Participants
|
2 Participants
|
1 Participants
|
3 Participants
|
3 Participants
|
2 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
|
Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 1
Temp, decrease to <=35
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 1
Temp, change to normal or no change
|
1 Participants
|
1 Participants
|
3 Participants
|
4 Participants
|
4 Participants
|
2 Participants
|
4 Participants
|
8 Participants
|
2 Participants
|
6 Participants
|
|
Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 1
Temp, increase to >=38
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)Population: Part 2 MM Population
The following criteria was used to flag vital signs of potential clinical importance: change from Baseline in heart rate (decrease to \<60 bpm and increase to \>100 bpm) and change in temperature from Baseline(increase to \>=38 or decrease to \<=35 degrees celsius). Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=35 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (MM)
HR, decrease to <60
|
9 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (MM)
HR, change to normal or no change
|
17 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (MM)
HR, increase to >100
|
10 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (MM)
Temp, decrease to <=35
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (MM)
Temp, change to normal or no change
|
29 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (MM)
Temp, increase to >=38
|
5 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)Population: Part 2 NHL Population
The following criteria was used to flag vital signs of potential clinical importance: change from Baseline in heart rate (decrease to \<60 bpm and increase to \>100 bpm) and change in temperature from Baseline(increase to \>=38 or decrease to \<=35 degrees celsius). Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=6 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (NHL)
HR, decrease to <60
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (NHL)
HR, change to normal or no change
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (NHL)
HR, increase to >100
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (NHL)
Temp, decrease to <=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (NHL)
Temp, change to normal or no change
|
5 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (NHL)
Temp, increase to >=38
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)Population: Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Blood samples were collected for the analysis of following clinical chemistry parameters: albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (T.Bil.), calcium (Ca), creatinine (Creat), creatinine kinase (CK), gamma glutamyl transferase (GGT), glucose (Gl), potassium (Pot), magnesium (Mg), sodium (Sod), phosphate (Ph) and urate. Values(Hyper and hypo)for Gl, Pot, Mg, Sod and Ca is presented. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. All increases are an increase in grade from Baseline. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=1 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
n=1 Participants
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=4 Participants
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=4 Participants
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=4 Participants
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=3 Participants
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=4 Participants
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
n=8 Participants
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=3 Participants
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
n=6 Participants
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Ph,any grade increase,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Ph,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
ALP,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
GGT,increase to Grade 3,n=1,1,4,4,3,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Sod,Hyper,any grade increase,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Ph,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Gl, Hyper,any grade increase,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
4 Participants
|
0 Participants
|
4 Participants
|
6 Participants
|
0 Participants
|
4 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Gl, Hyper,increase toGrade 3,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Gl, Hyper,increase toGrade 4,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Gl, Hypo,any grade increase,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
CK,increase to Grade 3,n=1,1,4,4,3,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Gl, Hypo,increase toGrade 3,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Gl, Hypo,increase toGrade 4,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Albumin,any grade increase,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
3 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Albumin,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Albumin,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
ALP,any grade increase,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
2 Participants
|
5 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
ALP,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
ALT,any grade increase,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
5 Participants
|
1 Participants
|
5 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
ALT,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
ALT,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
AST,any grade increase,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
1 Participants
|
2 Participants
|
2 Participants
|
1 Participants
|
1 Participants
|
3 Participants
|
6 Participants
|
3 Participants
|
5 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
AST,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
AST,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
T.Bil.,any grade increase,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
T.Bil.,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
T.Bil.,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
CK,any grade increase,n=1,1,4,4,3,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
3 Participants
|
3 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
CK,increase to Grade 4,n=1,1,4,4,3,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Creat,any grade increase,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
2 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Creat,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Creat,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
GGT,any grade increase,1,1,4,4,3,3,4,8,3,6
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
3 Participants
|
3 Participants
|
3 Participants
|
4 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
GGT,increase to Grade 4,n=1,1,4,4,3,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Pot,Hyper,any grade increase,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Pot,Hyper,increase to Grade3,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Pot,Hyper,increase to Grade4,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Pot,Hypo,any grade increase,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Pot,Hypo,increase to Grade3,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Pot,Hypo,increase to Grade4,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Mg,Hyper,any grade increase,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Mg,Hyper,increase to Grade3,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Mg,Hyper,increase to Grade4,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Mg,Hypo,any grade increase,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
0 Participants
|
3 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Mg,Hypo,increase to Grade3,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Mg,Hypo,increase to Grade 4,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Sod,Hyper,increase to Grade3,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Sod,Hyper,increase to Grade4,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Sod,Hypo,any grade increase,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
2 Participants
|
1 Participants
|
3 Participants
|
2 Participants
|
0 Participants
|
3 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Sod,Hypo,increase to Grade3,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Sod,Hypo,increase to Grade4,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Urate,any grade increase,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Urate,increase to Grade 3,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Urate,increase to Grade4,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Ca,Hyper,any grade increase,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
3 Participants
|
2 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Ca,Hyper,increase to Grade3,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Ca,Hyper,increase to Grade4,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Ca,Hypo,any grade increase,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Ca,Hypo,increase to Grade3,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 1
Ca,Hypo,increase to Grade4,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)Population: Part 2 MM Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Blood samples were collected for the analysis of following clinical chemistry parameters: albumin,ALP,ALT,AST,T.Bil.,Ca, Creat,CK, GGT,Gl, Pot,Mg, Sod, Ph and urate. Values(Hyper and hypo)for Gl, Pot, Mg, Sod and Ca is presented. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. All increases are an increase in grade from Baseline. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=35 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Ca,Hypocalcemia,increase to Grade 3,n=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Gl, Hyperglycemia,any grade increase,n=35
|
19 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Gl, Hyperglycemia,increase to Grade 3,n=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Gl, Hyperglycemia,increase to Grade 4,n=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Gl, Hypoglycemia,any grade increase,n=35
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Gl, Hypoglycemia,increase to Grade 3,n=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Gl, Hypoglycemia,increase to Grade 4,n=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Albumin,any grade increase,n=35
|
15 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Albumin,increase to Grade 3,n=35
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Albumin,increase to Grade 4,n=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
ALP,any grade increase,n=35
|
19 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
ALP,increase to Grade 3,n=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
ALP,increase to Grade 4,,n=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
ALT,any grade increase,n=35
|
19 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
ALT,increase to Grade 3,n=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
ALT,increase to Grade 4,n=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
AST,any grade increase,n=35
|
29 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
AST,increase to Grade 3,n=35
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
AST,increase to Grade 4,n=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Total bilirubin,any grade increase,n=35
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Total bilirubin,increase to Grade 3,n=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Total bilirubin,increase to Grade 4,n=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
CK,any grade increase,n=35
|
15 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
CK,increase to Grade 3,n=35
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
CK,increase to Grade 4 ,n=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Creatinine,any grade increase,n=35
|
7 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Creatinine,increase to Grade 3,n=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Creatinine,increase to Grade 4,n=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
GGT,any grade increase,n=34
|
21 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
GGT,increase to Grade 3,n=34
|
6 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
GGT,increase to Grade 4,n=34
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Pot,Hyperkalemia,any grade increase,n=35
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Pot,Hyperkalemia,increase to Grade 3,n=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Pot,Hyperkalemia,increase to Grade 4,n=35
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Pot,Hypokalemia,any grade increase,n=35
|
12 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Pot,Hypokalemia,increase to Grade 3,n=35
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Pot,Hypokalemia,increase to Grade 4,n=35
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Mg,Hypermagnesemia,any grade increase,n=34
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Mg,Hypermagnesemia,increase to Grade 3,n=34
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Mg,Hypermagnesemia,increase to Grade 4,n=34
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Mg,Hypomagnesemia,any grade increase,n=34
|
9 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Mg,Hypomagnesemia,increase to Grade 3,n=34
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Mg,Hypomagnesemia,increase to Grade 4,n=34
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Phosphate,any grade increase,n=35
|
8 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Phosphate,increase to Grade 3,n=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Phosphate,increase to Grade 4,n=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Sod,Hypernatremia,any grade increase,n=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Sod,Hypernatremia,increase to Grade 3,n=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Sod,Hypernatremia,increase to Grade 4,n=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Sod,Hyponatremia,any grade increase,n=35
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Sod,Hyponatremia,increase to Grade 3,n=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Sod,Hyponatremia,increase to Grade 4,n=35
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Urate,any grade increase,n=35
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Urate,increase to Grade 3,n=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Urate,increase to Grade 4,n=35
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Ca,Hypercalcemia,any grade increase,n=35
|
8 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Ca,Hypercalcemia,increase to Grade 3,n=35
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Ca,Hypercalcemia,increase to Grade 4,,n=35
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Ca,Hypocalcemia,any grade increase,n=35
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (MM)
Ca,Hypocalcemia,increase to Grade 4,n=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)Population: Part 2 NHL Population. Only those participants with data available at the specified data points were analyzed.
Blood samples were collected for the analysis of following clinical chemistry parameters: albumin, ALP, ALT, AST, Bilirubin, Ca, Creat, CK, GGT, Glucose, Pot, Mg, Sod, and Ph. Values(Hyper and hypo)for Glucose, Pot, Mg, Sod and Ca is presented. Laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. All increases are an increase in grade from Baseline. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=5 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
ALP,any grade increase
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
ALP,increase to Grade 3
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Pot,Hyperkalemia,increase to Grade 3
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Pot,Hyperkalemia,any grade increase
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Pot,Hyperkalemia,increase to Grade 4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Pot,Hypokalemia,any grade increase
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Pot,Hypokalemia,increase to Grade 3
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Pot,Hypokalemia,increase to Grade 4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Mg,Hypermagnesemia,any grade increase
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Mg,Hypermagnesemia,increase to Grade 3
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Mg,Hypermagnesemia,increase to Grade 4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Mg,Hypomagnesemia,any grade increase
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Gl, Hyperglycemia,any grade increase
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Gl, Hyperglycemia,increase to Grade 3
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Gl, Hyperglycemia,increase to Grade 4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Gl, Hypoglycemia,any grade increase
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Gl, Hypoglycemia,increase to Grade 3
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Gl, Hypoglycemia,increase to Grade 4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Albumin,any grade increase
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Albumin,increase to Grade 3
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Albumin,increase to Grade 4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
ALP,increase to Grade 4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
ALT,any grade increase
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
ALT,increase to Grade 3
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
ALT,increase to Grade 4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
AST,any grade increase
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
AST,increase to Grade 3
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
AST,increase to Grade 4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Total bilirubin,any grade increase
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Total bilirubin,increase to Grade 3
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Total bilirubin,increase to Grade 4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
CK,any grade increase
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
CK,increase to Grade 3
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
CK,increase to Grade 4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Creatinine,any grade increase
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Creatinine,increase to Grade 3
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Creatinine,increase to Grade 4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
GGT,any grade increase
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
GGT,increase to Grade 3
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
GGT,increase to Grade 4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Mg,Hypomagnesemia,increase to Grade 3
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Mg,Hypomagnesemia,increase to Grade 4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Phosphate,any grade increase
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Phosphate,increase to Grade 3
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Phosphate,increase to Grade 4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Sod,Hypernatremia,any grade increase
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Sod,Hypernatremia,increase to Grade 3
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Sod,Hypernatremia,increase to Grade 4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Sod,Hyponatremia,any grade increase
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Sod,Hyponatremia,increase to Grade 3
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Sod,Hyponatremia,increase to Grade 4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Ca,Hypercalcemia,any grade increase
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Ca,Hypercalcemia,increase to Grade 3
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Ca,Hypercalcemia,increase to Grade 4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Ca,Hypocalcemia,any grade increase
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Ca,Hypocalcemia,increase to Grade 3
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Clinical Chemistry Data-Part 2 (NHL)
Ca,Hypocalcemia,increase to Grade 4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)Population: Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Blood samples were collected for the analysis of following clinical chemistry parameters: direct bilirubin (D.Bil.), chloride, carbon dioxide (CO2), lactate dehydrogenase (LDH), total protein (T.Pro) and urea or blood urea nitrogen (BUN). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. A laboratory value that is outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or No Change (NC)' category. Participants were counted twice if the participant "Decreased to low" and "Increased to high" during post-Baseline. Data for worst-case post Baseline is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=1 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
n=1 Participants
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=4 Participants
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=4 Participants
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=4 Participants
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=3 Participants
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=4 Participants
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
n=8 Participants
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=3 Participants
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
n=6 Participants
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 1
CO2,decrease to low,n=1,1,4,4,4,3,4,8,3,6
|
1 Participants
|
1 Participants
|
1 Participants
|
3 Participants
|
1 Participants
|
1 Participants
|
3 Participants
|
2 Participants
|
2 Participants
|
2 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 1
LDH,to normal or NC,n=n=1,1,4,4,3,3,4,8,3,6
|
1 Participants
|
1 Participants
|
2 Participants
|
2 Participants
|
1 Participants
|
2 Participants
|
1 Participants
|
5 Participants
|
1 Participants
|
1 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 1
LDH,increase to high,n=1,1,4,4,3,3,4,8,3,6
|
0 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
3 Participants
|
3 Participants
|
2 Participants
|
5 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 1
T.Pro,decrease to low,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
2 Participants
|
0 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 1
T.Pro,to normal or NC,n=1,1,4,4,4,3,4,8,3,6
|
1 Participants
|
1 Participants
|
4 Participants
|
3 Participants
|
2 Participants
|
2 Participants
|
3 Participants
|
6 Participants
|
1 Participants
|
4 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 1
D.Bil.,decrease to low,n=1,1,4,2,2,3,4,4,3,5
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 1
D.Bil.,to normal or NC, n=1,1,4,2,2,3,4,4,3,5
|
1 Participants
|
1 Participants
|
3 Participants
|
2 Participants
|
1 Participants
|
3 Participants
|
4 Participants
|
3 Participants
|
3 Participants
|
3 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 1
D.Bil.,increase to high,n=1,1,4,2,2,3,4,4,3,5
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 1
Chloride,decrease to low,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
1 Participants
|
3 Participants
|
0 Participants
|
3 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 1
Chloride,to normal or NC,n=1,1,4,4,4,3,4,8,3,6
|
1 Participants
|
1 Participants
|
3 Participants
|
4 Participants
|
2 Participants
|
2 Participants
|
3 Participants
|
4 Participants
|
2 Participants
|
3 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 1
T.Pro,increase to high,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 1
Chloride,increase to high,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 1
CO2, to normal or NC,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
3 Participants
|
1 Participants
|
3 Participants
|
2 Participants
|
0 Participants
|
5 Participants
|
1 Participants
|
4 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 1
CO2,increase to high,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 1
LDH,decrease to low,n=1,1,4,4,3,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 1
BUN,decrease to low,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 1
BUN,to normal or NC,n=1,1,4,4,4,3,4,8,3,6
|
1 Participants
|
1 Participants
|
2 Participants
|
3 Participants
|
2 Participants
|
3 Participants
|
3 Participants
|
5 Participants
|
2 Participants
|
3 Participants
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 1
BUN,increase to high,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
1 Participants
|
1 Participants
|
PRIMARY outcome
Timeframe: Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)Population: Part 2 MM Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Blood samples were collected for the analysis of following clinical chemistry parameters: D.Bil., chloride, CO2, LDH, T.Pro and BUN. Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits.A laboratory value that is outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline.Data for worst-case post Baseline is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=35 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (MM)
LDH,increase to high,n=35
|
17 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (MM)
T.Pro,decrease to low,n=35
|
11 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (MM)
T.Pro, to normal or no change,n=35
|
18 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (MM)
T.Pro,increase to high,n=35
|
7 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (MM)
BUN,decrease to low,n=35
|
8 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (MM)
BUN, to normal or no change,n=35
|
23 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (MM)
BUN,increase to high,n=35
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (MM)
D.Bil.,decrease to low,n=30
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (MM)
D.Bil., to normal or no change,n=30
|
20 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (MM)
D.Bil.,increase to high,n=30
|
8 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (MM)
Chloride,decrease to low,n=35
|
7 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (MM)
Chloride, to normal or no change,n=35
|
25 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (MM)
Chloride,increase to high,n=35
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (MM)
CO2,decrease to low,n=35
|
8 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (MM)
CO2, to normal or no change,n=35
|
23 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (MM)
CO2,increase to high,n=35
|
5 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (MM)
LDH,decrease to low,n=35
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (MM)
LDH, to normal or no change,n=35
|
17 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)Population: Part 2 NHL Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Blood samples were collected for the analysis of following clinical chemistry parameters: D.Bil., chloride, CO2, LDH, and T.Pro. Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits.A laboratory value that is outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline. Data for worst-case post Baseline is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=5 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (NHL)
D.Bil.,decrease to low,n=2
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (NHL)
D.Bil., to normal or no change,n=2
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (NHL)
D.Bil.,increase to high,n=2
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (NHL)
Chloride,decrease to low,n=5
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (NHL)
Chloride, to normal or no change,n=5
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (NHL)
Chloride,increase to high,n=5
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (NHL)
CO2,decrease to low,n=5
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (NHL)
CO2, to normal or no change,n=5
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (NHL)
CO2,increase to high,n=5
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (NHL)
LDH,decrease to low,n=5
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (NHL)
LDH, to normal or no change,n=5
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (NHL)
LDH,increase to high,n=5
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (NHL)
T.Pro,decrease to low,n=5
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (NHL)
T.Pro, to normal or no change,n=5
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Clinical Chemistry Data With Respect to Normal Range-Part 2 (NHL)
T.Pro,increase to high,n=5
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)Population: Part 1 Population
Blood samples were collected for the analysis of following hematology parameters: hemoglobin (Hb), lymphocytes (Lymph), neutrophils (Neutro), platelet count (PC), and leukocytes (leuko). The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=1 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
n=1 Participants
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=4 Participants
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=4 Participants
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=4 Participants
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=3 Participants
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=4 Participants
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
n=8 Participants
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=3 Participants
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
n=6 Participants
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1
Leuko, Leukocytosis, increase to Grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1
Leuko, Leuko decreased, increase to Grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1
Leuko, Leuko decreased, increase to Grade 4
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1
Hb, Hb increased, increase to Grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1
Lymph, Lymph count decreased, any grade increase
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
2 Participants
|
4 Participants
|
2 Participants
|
3 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1
Neutro, any grade increase
|
1 Participants
|
1 Participants
|
2 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
4 Participants
|
2 Participants
|
3 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1
Hb, Hb increased, any grade increase
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1
Hb, Hb increased, increase to Grade 4
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1
Hb,Anemia, any grade increase
|
1 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
2 Participants
|
2 Participants
|
1 Participants
|
3 Participants
|
2 Participants
|
4 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1
Hb, Anemia, increase to Grade 3
|
0 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1
Hb, Anemia, increase to Grade 4
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1
Lymph, Lymph count increased, any grade increase
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1
Lymph, Lymph count increased, increase to Grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1
Lymph, Lymph count decreased, increase to Grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
4 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1
Lymph, Lymph count decreased, increase to Grade 4
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1
Neutro, increase to Grade 3
|
0 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1
Neutro, increase to Grade 4
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1
PC, any grade increase
|
1 Participants
|
1 Participants
|
2 Participants
|
3 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
6 Participants
|
3 Participants
|
6 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1
Leuko, Leukocytosis, any grade increase
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1
PC, increase to Grade 3
|
1 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
4 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1
PC, increase to Grade 4
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1
Leuko, Leukocytosis, increase to Grade 4
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1
Leuko, Leuko decreased, any grade increase
|
1 Participants
|
1 Participants
|
3 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
3 Participants
|
1 Participants
|
2 Participants
|
3 Participants
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 1
Lymph, Lymph count increased, increase to Grade 4
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)Population: Part 2 MM Population
Blood samples were collected for the analysis of following hematology parameters: Hb, Lymph, Neutro, PC, and leuko. The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits.An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=35 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)
Lymph, Lymph count decreased, increase to Grade 3
|
8 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)
Lymph, Lymph count decreased, increase to Grade 4
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)
Neutro, any grade increase
|
15 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)
Neutro, increase to Grade 3
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)
Neutro, increase to Grade 4
|
5 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)
Hb, Hb increased, any grade increase
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)
Hb, Hb increased, increase to Grade 3
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)
Hb, Hb increased, increase to Grade 4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)
Hb,Anemia, any grade increase
|
18 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)
Hb, Anemia, increase to Grade 3
|
7 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)
Hb, Anemia, increase to Grade 4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)
Lymph, Lymph count increased, any grade increase
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)
Lymph, Lymph count increased, increase to Grade 3
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)
PC, any grade increase
|
32 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)
PC, increase to Grade 3
|
13 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)
PC, increase to Grade 4
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)
Leuko, Leukocytosis, any grade increase
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)
Leuko, Leukocytosis, increase to Grade 3
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)
Leuko, Leukocytosis, increase to Grade 4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)
Leuko, Leuko decreased, any grade increase
|
16 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)
Lymph, Lymph count increased, increase to Grade 4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)
Lymph, Lymph count decreased, any grade increase
|
18 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)
Leuko, Leuko decreased, increase to Grade 3
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (MM)
Leuko, Leuko decreased, increase to Grade 4
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)Population: Part 2 NHL Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Blood samples were collected for the analysis of following hematology parameters: Hb, Lymph, Neutro, PC, and leuko. The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Data for worst-case post Baseline is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=6 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)
Leuko, Leukocytosis, increase to Grade 3, n=6
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)
Hb, Hb increased, any grade increase, n=6
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)
Hb, Hb increased, increase to Grade 3, n=6
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)
Hb, Hb increased, increase to Grade 4, n=6
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)
Hb,Anemia, any grade increase, n=6
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)
Hb, Anemia, increase to Grade 3, n=6
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)
Hb, Anemia, increase to Grade 4, n=6
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)
Lymph,Lymph count increased,any grade increase,n=6
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)
Lymph,Lymph count increased,increase to Grade3,n=6
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)
Lymph,Lymph count increased,increase to Grade4,n=6
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)
Lymph,Lymph count decreased,any grade increase,n=6
|
5 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)
Lymph,Lymph count decreased,increase to Grade3,n=6
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)
Lymph,Lymph count decreased,increase to Grade4,n=6
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)
Neutro, any grade increase, n=6
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)
Neutro, increase to Grade 3, n=6
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)
Neutro, increase to Grade 4, n=6
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)
PC, any grade increase, n=5
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)
PC, increase to Grade 3, n=5
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)
PC, increase to Grade 4, n=5
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)
Leuko, Leukocytosis, any grade increase, n=6
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)
Leuko, Leukocytosis, increase to Grade 4, n=6
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)
Leuko, Leuko decreased, any grade increase, n=6
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)
Leuko, Leuko decreased, increase to Grade 3, n=6
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Grade Change From Baseline in Hematology Data-Part 2 (NHL)
Leuko, Leuko decreased, increase to Grade 4, n=6
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)Population: Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Blood samples were collected for the analysis of following hematology parameters: basophils (Baso), eosinophils (Eosino), hematocrit (Hct), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), monocytes (Mono), erythrocytes (Erythro) and reticulocytes (Reticu). A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline.Data at worst-case post Baseline is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=1 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
n=1 Participants
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=4 Participants
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=4 Participants
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=4 Participants
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=3 Participants
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=4 Participants
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
n=8 Participants
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=3 Participants
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
n=6 Participants
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
Baso,increase to high,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
Eosino,decrease to low,n=1,1,4,4,4,3,4,8,3,6
|
1 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
Eosino,to normal or NC,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
1 Participants
|
3 Participants
|
4 Participants
|
4 Participants
|
2 Participants
|
4 Participants
|
8 Participants
|
3 Participants
|
4 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
Eosino,increase to high,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
Hct,increase to high,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
MCH,decrease to low,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
3 Participants
|
1 Participants
|
1 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
MCH,increase to high,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
MCV,decrease to low,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
Reticu,increase to high,n=1,1,3,3,2,1,4,8,2,6
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
3 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
Hct,decrease to low,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
Hct, to normal or NC,n=1,1,4,4,4,3,4,8,3,6
|
1 Participants
|
1 Participants
|
4 Participants
|
3 Participants
|
4 Participants
|
2 Participants
|
4 Participants
|
7 Participants
|
1 Participants
|
6 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
MCH, to normal or NC,n=1,1,4,4,4,3,4,8,3,6
|
1 Participants
|
1 Participants
|
4 Participants
|
4 Participants
|
3 Participants
|
3 Participants
|
1 Participants
|
5 Participants
|
2 Participants
|
5 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
MCHC,decrease to low,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
3 Participants
|
1 Participants
|
1 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
MCHC, to normal or NC,n=1,1,4,4,4,3,4,8,3,6
|
1 Participants
|
0 Participants
|
4 Participants
|
3 Participants
|
4 Participants
|
2 Participants
|
3 Participants
|
5 Participants
|
2 Participants
|
5 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
MCHC,increase to high,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
MCV, to normal or NC,n=1,1,4,4,4,3,4,8,3,6
|
1 Participants
|
0 Participants
|
4 Participants
|
4 Participants
|
4 Participants
|
3 Participants
|
2 Participants
|
8 Participants
|
2 Participants
|
5 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
MCV,increase to high,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
Mono,decrease to low,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
Mono, to normal or NC,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
1 Participants
|
3 Participants
|
3 Participants
|
4 Participants
|
3 Participants
|
2 Participants
|
5 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
Mono,increase to high,n=1,1,4,4,4,3,4,8,3,6
|
1 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
3 Participants
|
3 Participants
|
5 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
Erythro,decrease to low,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
Erythro, to normal or NC,n=1,1,4,4,4,3,4,8,3,6
|
1 Participants
|
1 Participants
|
4 Participants
|
4 Participants
|
4 Participants
|
3 Participants
|
3 Participants
|
6 Participants
|
2 Participants
|
6 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
Erythro,increase to high,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
Reticu,decrease to low,n=1,1,3,3,2,1,4,8,2,6
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
1 Participants
|
1 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
Reticu,to normal or NC,n=1,1,3,3,2,1,4,8,2,6
|
1 Participants
|
1 Participants
|
1 Participants
|
3 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
4 Participants
|
1 Participants
|
4 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
Baso,decrease to low,n=1,1,4,4,4,3,4,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 1
Baso, to normal or NC,n=1,1,4,4,4,3,4,8,3,6
|
1 Participants
|
1 Participants
|
4 Participants
|
4 Participants
|
4 Participants
|
3 Participants
|
3 Participants
|
8 Participants
|
3 Participants
|
3 Participants
|
PRIMARY outcome
Timeframe: Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)Population: Part 2 MM Population.Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Blood samples were collected for the analysis of following hematology parameters: Baso, Eosino, Hct, MCHC, MCH, MCV, Mono, Erythro and Reticu. A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline.Data at worst-case post Baseline is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=35 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
Baso,decrease to low,n=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
Baso, to normal or NC,n=35
|
33 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
Baso,increase to high,n=35
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
Eosino,decrease to low,n=35
|
7 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
Eosino,to normal or NC,n=35
|
26 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
Eosino,increase to high,n=35
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
Hct,decrease to low,n=35
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
Hct, to normal or NC,n=35
|
31 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
Hct,increase to high,n=35
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
MCH,decrease to low,n=35
|
7 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
MCH, to normal or NC,n=35
|
28 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
MCH,increase to high,n=35
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
MCHC,decrease to low,n=35
|
5 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
MCHC, to normal or NC,n=35
|
28 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
MCHC,increase to high,n=35
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
MCV,decrease to low,n=35
|
6 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
MCV, to normal or NC,n=35
|
28 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
MCV,increase to high,n=35
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
Mono,decrease to low,n=35
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
Mono, to normal or NC,n=35
|
18 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
Mono,increase to high,n=35
|
14 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
Erythro,decrease to low,n=35
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
Erythro, to normal or NC,n=35
|
31 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
Erythro,increase to high,n=35
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
Reticu,decrease to low,n=28
|
10 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
Reticu, to normal or NC,n=28
|
14 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (MM)
Reticu,increase to high,n=28
|
8 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)Population: Part 2 NHL Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Blood samples were collected for the analysis of following hematology parameters: Baso, Eosino, Hct, MCHC, MCH, MCV, Mono, Erythro and Reticu. A laboratory value that was outside the reference range was considered either high abnormal (value above the upper limit of the reference range) or low abnormal (value below the lower limit of the reference range). Baseline was defined as latest pre-dose assessment with a non-missing value, including unscheduled visits. If values were unchanged (example: High to High), or whose value became normal, were recorded in the 'To Normal or NC' category. Participants were counted twice if the participant 'Decreased to Low' and 'Increased to High' during post-Baseline. Data at worst-case post Baseline is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=6 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
Baso,decrease to low,n=6
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
Reticu,increase to high,n=5
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
Baso, to normal or NC,n=6
|
6 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
Baso,increase to high,n=6
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
Eosino,decrease to low,n=6
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
Eosino,to normal or NC,n=6
|
6 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
Eosino,increase to high,n=6
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
Hct,decrease to low,n=6
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
Hct, to normal or NC,n=6
|
5 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
Hct,increase to high,n=6
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
MCH,decrease to low,n=6
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
MCH, to normal or NC,n=6
|
5 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
MCH,increase to high,n=6
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
MCHC,decrease to low,n=6
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
MCHC, to normal or NC,n=6
|
5 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
MCHC,increase to high,n=6
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
MCV,decrease to low,n=6
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
MCV, to normal or NC,n=6
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
MCV,increase to high,n=6
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
Mono,decrease to low,n=6
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
Mono, to normal or NC,n=6
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
Mono,increase to high,n=6
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
Erythro,decrease to low,n=6
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
Erythro, to normal or NC,n=6
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
Erythro,increase to high,n=6
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
Reticu,decrease to low,n=5
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Change From Baseline in Hematology Data With Respect to Normal Range-Part 2 (NHL)
Reticu, to normal or NC,n=5
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)Population: Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Urine samples were collected to assess urine occult blood (OB) and urine protein (Pro). The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased, increase to small (indicated by trace and 1+), increase to moderate (indicated by 2+) and increase to large (indicated by 3+ and above) for urine OB and no change/decreased, increase to trace, increase to 1+, increase to 2+ and increase to 3+ for urine Pro indicating proportional concentrations in the urine sample. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=1 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
n=1 Participants
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=4 Participants
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=4 Participants
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=4 Participants
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=3 Participants
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=4 Participants
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
n=8 Participants
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=3 Participants
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
n=6 Participants
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 1
OB,Increase to moderate, n=1,1,4,4,2,3,3,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 1
OB,No change/decreased, n=1,1,4,4,2,3,3,8,3,6
|
1 Participants
|
1 Participants
|
3 Participants
|
3 Participants
|
1 Participants
|
2 Participants
|
1 Participants
|
5 Participants
|
2 Participants
|
5 Participants
|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 1
OB,Increase to large, n=1,1,4,4,2,3,3,8,3,6
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 1
Pro,No change/decreased, n=1,1,4,3,2,3,4,5,3,5
|
1 Participants
|
0 Participants
|
3 Participants
|
3 Participants
|
2 Participants
|
1 Participants
|
3 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 1
Pro,Increase to trace, n=1,1,4,3,2,3,4,5,3,5
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
4 Participants
|
2 Participants
|
1 Participants
|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 1
Pro,Increase to 1+, n=1,1,4,3,2,3,4,5,3,5
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 1
Pro,Increase to 2+, n=1,1,4,3,2,3,4,5,3,5
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 1
Pro,Increase to 3+, n=1,1,4,3,2,3,4,5,3,5
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 1
OB,Increase to small, n=1,1,4,4,2,3,3,8,3,6
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
3 Participants
|
1 Participants
|
0 Participants
|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 1
Pro,Unknown, n=1,1,4,3,2,3,4,5,3,5
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
PRIMARY outcome
Timeframe: Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)Population: Part 2 MM Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Urine samples were collected to assess urine OB and urine Pro. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased, increase to small (indicated by trace and 1+), increase to moderate (indicated by 2+) and increase to large (indicated by 3+ and above) for urine OB and no change/decreased, increase to trace, increase to 1+, increase to 2+ and increase to 3+ for urine Pro indicating proportional concentrations in the urine sample. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=35 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (MM)
Pro,Increase to trace, n=31
|
11 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (MM)
OB,Increase to moderate, n=33
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (MM)
OB,Increase to large, n=33
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (MM)
Pro,No change/decreased, n=31
|
15 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (MM)
OB,No change/decreased, n=33
|
18 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (MM)
OB,Increase to small, n=33
|
14 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (MM)
Pro,Increase to 1+, n=31
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (MM)
Pro,Increase to 2+, n=31
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (MM)
Pro,Increase to 3+, n=31
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (MM)
Pro,Unknown, n=31
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline and Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)Population: Part 2 NHL Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Urine samples were collected to assess urine OB and urine Pro. The dipstick test gave results in a semi-quantitative manner, and results for urinalysis parameters were recorded as no change/decreased, increase to small (indicated by trace and 1+), increase to moderate (indicated by 2+) and increase to large (indicated by 3+ and above) for urine OB. For Urine Pro., results were reported as no change/decreased, increase to trace, increase to 1+, increase to 2+ and increase to 3+ indicating proportional concentrations in the urine sample. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=5 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (NHL)
OB,Increase to large, n=5
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (NHL)
Pro,No change/decreased, n=4
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (NHL)
Pro,Increase to trace, n=4
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (NHL)
Pro,Increase to 1+, n=4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (NHL)
Pro,Increase to 2+, n=4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (NHL)
Pro,Increase to 3+, n=4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (NHL)
OB,No change/decreased, n=5
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (NHL)
OB,Increase to small, n=5
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Worst-case Urinalysis Results Post-Baseline Relative to Baseline by Dipstick Method -Part 2 (NHL)
OB,Increase to moderate, n=5
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline and Day 1 (Cycle 2 and 3)Population: Part 1 Population. NA indicates that standard deviation could not be calculated for a single participant.
Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=1 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.06 mg/kg
Day 1 (Cycle 2)
|
-0.0 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.06 mg/kg
Day 1 (Cycle 3)
|
0.3 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline and Day 1 (Cycle 2)Population: Part 1 Population. Only those participants with data available at the specified data points were analyzed.
Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=3 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.03 mg/kg and 0.12 mg/kg
|
0.4 Grams per day
Standard Deviation 0.72
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13,14, 15)Population: Part 1 Population. Only those participants with data available at the specified data points were analyzed. NA indicates that standard deviation could not be calculated for a single participant.
Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=1 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.24 mg/kg
Day 1 (Cycle 2)
|
-0.0 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.24 mg/kg
Day 1 (Cycle 3)
|
-0.0 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.24 mg/kg
Day 1 (Cycle 4)
|
88.1 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.24 mg/kg
Day 1 (Cycle 5)
|
-0.1 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.24 mg/kg
Day 1 (Cycle 6)
|
-0.0 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.24 mg/kg
Day 1 (Cycle 7)
|
-0.0 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.24 mg/kg
Day 1 (Cycle 8)
|
-0.1 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.24 mg/kg
Day 1 (Cycle 9)
|
-0.1 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.24 mg/kg
Day 1 (Cycle 10)
|
-0.1 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.24 mg/kg
Day 1 (Cycle 12)
|
-0.1 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.24 mg/kg
Day 1 (Cycle 13)
|
-0.1 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.24 mg/kg
Day 1 (Cycle 14)
|
-0.1 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.24 mg/kg
Day 1 (Cycle 15)
|
-0.1 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline and Day 1 (Cycle 2, 3, 5, 6, 7, 8)Population: Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). NA indicates that standard deviation could not be calculated for a single participant.
Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=4 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.48 mg/kg
Day 1 (Cycle 6), n=1
|
0.1 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.48 mg/kg
Day 1 (Cycle 7), n=1
|
0.1 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.48 mg/kg
Day 1 (Cycle 8), n=1
|
0.1 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.48 mg/kg
Day 1 (Cycle 2), n=2
|
0.0 Grams per day
Standard Deviation 0.04
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.48 mg/kg
Day 1 (Cycle 3), n=1
|
0.8 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.48 mg/kg
Day 1 (Cycle 5), n=1
|
0.1 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline and Day 1 (Cycle 2, 3, 4, 5, 6)Population: Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). NA indicates that standard deviation could not be calculated for a single participant.
Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=3 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.96 mg/kg
Day 1 (Cycle 5), n=1
|
0.0 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.96 mg/kg
Day 1 (Cycle 6), n=1
|
0.2 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.96 mg/kg
Day 1 (Cycle 2), n=2
|
0.2 Grams per day
Standard Deviation 0.35
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.96 mg/kg
Day 1 (Cycle 3), n=2
|
-0.1 Grams per day
Standard Deviation 0.07
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.96 mg/kg
Day 1 (Cycle 4), n=1
|
-0.1 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 11, 12, 13, 14, 16)Population: Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). NA indicates that standard deviation could not be calculated for a single participant.
Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=4 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 1.92 mg/kg
Day 1 (Cycle 2), n=3
|
-0.1 Grams per day
Standard Deviation 0.48
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 1.92 mg/kg
Day 1 (Cycle 3), n=3
|
-30.3 Grams per day
Standard Deviation 51.72
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 1.92 mg/kg
Day 1 (Cycle 5), n=3
|
0.2 Grams per day
Standard Deviation 1.42
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 1.92 mg/kg
Day 1 (Cycle 6), n=2
|
-0.6 Grams per day
Standard Deviation 0.99
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 1.92 mg/kg
Day 1 (Cycle 7), n=2
|
-0.6 Grams per day
Standard Deviation 1.16
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 1.92 mg/kg
Day 1 (Cycle 12), n=1
|
-1.4 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 1.92 mg/kg
Day 1 (Cycle 13), n=1
|
-1.4 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 1.92 mg/kg
Day 1 (Cycle 14), n=1
|
-1.4 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 1.92 mg/kg
Day 1 (Cycle 16), n=1
|
-1.3 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 1.92 mg/kg
Day 1 (Cycle 4), n=4
|
-22.4 Grams per day
Standard Deviation 45.06
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 1.92 mg/kg
Day 1 (Cycle 8), n=2
|
-0.6 Grams per day
Standard Deviation 1.06
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 1.92 mg/kg
Day 1 (Cycle 11), n=1
|
-1.4 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 10, 12, 13, 14, 15, 16)Population: Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). NA indicates that standard deviation could not be calculated for a single participant.
Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=8 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 2.50 mg/kg
Day 1 (Cycle 2), n=4
|
0.8 Grams per day
Standard Deviation 1.54
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 2.50 mg/kg
Day 1 (Cycle 3), n=2
|
-0.2 Grams per day
Standard Deviation 0.31
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 2.50 mg/kg
Day 1 (Cycle 4), n=2
|
-0.2 Grams per day
Standard Deviation 0.38
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 2.50 mg/kg
Day 1 (Cycle 5), n=1
|
0.0 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 2.50 mg/kg
Day 1 (Cycle 6), n=2
|
-0.2 Grams per day
Standard Deviation 0.33
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 2.50 mg/kg
Day 1 (Cycle 7), n=1
|
0.2 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 2.50 mg/kg
Day 1 (Cycle 16), n=1
|
-0.5 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 2.50 mg/kg
Day 1 (Cycle 8), n=1
|
-0.5 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 2.50 mg/kg
Day 1 (Cycle 10), n=1
|
-0.4 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 2.50 mg/kg
Day 1 (Cycle 12), n=1
|
-0.5 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 2.50 mg/kg
Day 1 (Cycle 13), n=1
|
-0.5 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 2.50 mg/kg
Day 1 (Cycle 14), n=1
|
-0.4 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 2.50 mg/kg
Day 1 (Cycle 15), n=1
|
-0.5 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)Population: Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). NA indicates that standard deviation could not be calculated for a single participant.
Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=3 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
n=6 Participants
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 3.40 mg/kg and 4.60 mg/kg
Day 1 (Cycle 2), n=2,5
|
-0.6 Grams per day
Standard Deviation 0.83
|
0.0 Grams per day
Standard Deviation 0.45
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 3.40 mg/kg and 4.60 mg/kg
Day 1 (Cycle 3), n=2,4
|
-0.6 Grams per day
Standard Deviation 0.81
|
-0.0 Grams per day
Standard Deviation 0.23
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 3.40 mg/kg and 4.60 mg/kg
Day 1 (Cycle 4), n=2,4
|
-0.7 Grams per day
Standard Deviation 0.79
|
-0.1 Grams per day
Standard Deviation 0.25
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 3.40 mg/kg and 4.60 mg/kg
Day 1 (Cycle 5), n=2,4
|
-0.6 Grams per day
Standard Deviation 0.78
|
-0.1 Grams per day
Standard Deviation 0.46
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 3.40 mg/kg and 4.60 mg/kg
Day 1 (Cycle 6), n=2,4
|
-0.6 Grams per day
Standard Deviation 0.80
|
-0.0 Grams per day
Standard Deviation 0.33
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 3.40 mg/kg and 4.60 mg/kg
Day 1 (Cycle 7), n=2,4
|
-0.6 Grams per day
Standard Deviation 0.79
|
-0.1 Grams per day
Standard Deviation 0.48
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 3.40 mg/kg and 4.60 mg/kg
Day 1 (Cycle 8), n=2,2
|
-0.6 Grams per day
Standard Deviation 0.80
|
0.1 Grams per day
Standard Deviation 0.15
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 3.40 mg/kg and 4.60 mg/kg
Day 1 (Cycle 9), n=1,2
|
-1.1 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
0.2 Grams per day
Standard Deviation 0.33
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 3.40 mg/kg and 4.60 mg/kg
Day 1 (Cycle 10), n=1,2
|
-1.1 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
-0.0 Grams per day
Standard Deviation 0.03
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 3.40 mg/kg and 4.60 mg/kg
Day 1 (Cycle 11), n=1,2
|
-1.2 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
-0.1 Grams per day
Standard Deviation 0.06
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 3.40 mg/kg and 4.60 mg/kg
Day 1 (Cycle 16), n=1,2
|
-1.2 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
0.4 Grams per day
Standard Deviation 0.11
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 3.40 mg/kg and 4.60 mg/kg
Day 1 (Cycle 12), n=1,2
|
-1.2 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
0.0 Grams per day
Standard Deviation 0.13
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 3.40 mg/kg and 4.60 mg/kg
Day 1 (Cycle 13), n=1,2
|
-1.1 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
0.0 Grams per day
Standard Deviation 0.09
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 3.40 mg/kg and 4.60 mg/kg
Day 1 (Cycle 14), n=1,2
|
-1.0 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
0.3 Grams per day
Standard Deviation 0.11
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 3.40 mg/kg and 4.60 mg/kg
Day 1 (Cycle 15), n=1,2
|
-1.1 Grams per day
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
0.1 Grams per day
Standard Deviation 0.10
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline and Day 1 (Cycle 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)Population: Part 2 MM Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=35 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (MM)
Day 1 (Cycle 12), n=10
|
-0.4 Grams per day
Standard Deviation 1.11
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (MM)
Day 1 (Cycle 13), n=9
|
-0.4 Grams per day
Standard Deviation 1.27
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (MM)
Day 1 (Cycle 14), n=9
|
-0.4 Grams per day
Standard Deviation 1.25
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (MM)
Day 1 (Cycle 15), n=9
|
-0.4 Grams per day
Standard Deviation 1.30
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (MM)
Day 1 (Cycle 16), n=9
|
-0.3 Grams per day
Standard Deviation 1.35
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (MM)
Day 1 (Cycle 7), n=14
|
-0.9 Grams per day
Standard Deviation 1.56
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (MM)
Day 1 (Cycle 8), n=16
|
-0.7 Grams per day
Standard Deviation 1.53
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (MM)
Day 1 (Cycle 9), n=13
|
-0.5 Grams per day
Standard Deviation 1.01
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (MM)
Day 1 (Cycle 10), n=12
|
-0.4 Grams per day
Standard Deviation 1.06
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (MM)
Day 1 (Cycle 11), n=10
|
-0.4 Grams per day
Standard Deviation 1.01
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (MM)
Day 1 (Cycle 2), n=24
|
-0.5 Grams per day
Standard Deviation 1.21
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (MM)
Day 1 (Cycle 3), n=18
|
-0.7 Grams per day
Standard Deviation 1.29
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (MM)
Day 1 (Cycle 4), n=13
|
-0.7 Grams per day
Standard Deviation 1.65
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (MM)
Day 1 (Cycle 5), n=15
|
-0.7 Grams per day
Standard Deviation 1.66
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (MM)
Day 1 (Cycle 6), n=14
|
-0.8 Grams per day
Standard Deviation 1.69
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline and Day 1 (Cycle 2)Population: Part 2 NHL Population. Only those participants with data available at the specified data points were analyzed.
Urine samples were collected to assess urine Protein. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Protein excretion (24 hour) is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=2 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Change From Baseline in Urine Protein Excretion (24 Hour)-Part 2 (NHL)
|
0.0 Grams per day
Standard Deviation 0.18
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Pre-dose, 30 minutes post start of infusion (SOI), at end of infusion (EOI), 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)Population: PK Part 1 Population comprised of Part 1 participants of All Treated Population who had atleast 1 non-missing (non-quantifiable, NQ values were considered non-missing) PK assessment. Only those participants with data available at the specified data points were analyzed.
Blood samples were collected at designated timepoints. Pharmacokinetic (PK) parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
n=1 Participants
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=4 Participants
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=3 Participants
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=3 Participants
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=2 Participants
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=1 Participants
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=4 Participants
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC[0-infinity]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1
|
—
|
215803.06 Hours*nanogram per milliliter
Geometric Coefficient of Variation NA
NA indicates that geometric coefficient of variation could not be calculated for a single participant.
|
767285.51 Hours*nanogram per milliliter
Geometric Coefficient of Variation 49.51
|
632339.28 Hours*nanogram per milliliter
Geometric Coefficient of Variation 101.14
|
2991509.97 Hours*nanogram per milliliter
Geometric Coefficient of Variation 72.12
|
9235256.20 Hours*nanogram per milliliter
Geometric Coefficient of Variation 46.65
|
18469186.92 Hours*nanogram per milliliter
Geometric Coefficient of Variation NA
NA indicates that geometric coefficient of variation could not be calculated for a single participant.
|
—
|
8355209.26 Hours*nanogram per milliliter
Geometric Coefficient of Variation 25.29
|
—
|
SECONDARY outcome
Timeframe: Pre-dose and EOI of Day 1 (Cycle 1)Population: PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)Population: PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
n=1 Participants
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=4 Participants
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=4 Participants
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=3 Participants
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=3 Participants
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=3 Participants
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
n=2 Participants
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=6 Participants
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1
|
—
|
200467.82 Hours*nanogram per milliliter
Geometric Coefficient of Variation NA
NA indicates that geometric coefficient of variation could not be calculated for a single participant.
|
633446.78 Hours*nanogram per milliliter
Geometric Coefficient of Variation 35.42
|
729443.84 Hours*nanogram per milliliter
Geometric Coefficient of Variation 91.22
|
2389114.19 Hours*nanogram per milliliter
Geometric Coefficient of Variation 51.12
|
4448319.69 Hours*nanogram per milliliter
Geometric Coefficient of Variation 79.51
|
9892863.42 Hours*nanogram per milliliter
Geometric Coefficient of Variation 51.81
|
23121531.16 Hours*nanogram per milliliter
Geometric Coefficient of Variation 6.59
|
9738914.76 Hours*nanogram per milliliter
Geometric Coefficient of Variation 38.82
|
—
|
SECONDARY outcome
Timeframe: Pre-dose and EOI of Day 1 (Cycle 1)Population: PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)Population: PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=1 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
n=1 Participants
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=4 Participants
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=4 Participants
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=3 Participants
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=3 Participants
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=3 Participants
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
n=3 Participants
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=6 Participants
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Area Under the Concentration-time Curve From Zero to Time of Last Quantifiable Concentration (AUC[0-tlast]) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM- Part 1
|
44260.79 Hours*nanogram per milliliter
Geometric Coefficient of Variation NA
NA indicates that geometric coefficient of variation could not be calculated for a single participant.
|
178485.20 Hours*nanogram per milliliter
Geometric Coefficient of Variation NA
NA indicates that geometric coefficient of variation could not be calculated for a single participant.
|
637783.48 Hours*nanogram per milliliter
Geometric Coefficient of Variation 35.67
|
694825.13 Hours*nanogram per milliliter
Geometric Coefficient of Variation 107.50
|
2170746.96 Hours*nanogram per milliliter
Geometric Coefficient of Variation 59.81
|
4492292.65 Hours*nanogram per milliliter
Geometric Coefficient of Variation 82.00
|
10093784.72 Hours*nanogram per milliliter
Geometric Coefficient of Variation 54.20
|
19239850.61 Hours*nanogram per milliliter
Geometric Coefficient of Variation 53.15
|
10131666.86 Hours*nanogram per milliliter
Geometric Coefficient of Variation 47.32
|
—
|
SECONDARY outcome
Timeframe: Pre-dose and EOI of Day 1 (Cycle 1)Population: PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)Population: PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
n=1 Participants
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=4 Participants
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=3 Participants
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=3 Participants
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=2 Participants
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=1 Participants
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=4 Participants
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Clearance (CL) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1
|
—
|
28.27 Milliliter per hour
Geometric Coefficient of Variation NA
NA indicates that geometric coefficient of variation could not be calculated for a single participant.
|
10.53 Milliliter per hour
Geometric Coefficient of Variation 58.94
|
25.01 Milliliter per hour
Geometric Coefficient of Variation 88.61
|
15.10 Milliliter per hour
Geometric Coefficient of Variation 75.16
|
8.46 Milliliter per hour
Geometric Coefficient of Variation 27.46
|
11.68 Milliliter per hour
Geometric Coefficient of Variation NA
NA indicates that geometric coefficient of variation could not be calculated for a single participant.
|
—
|
38.84 Milliliter per hour
Geometric Coefficient of Variation 37.53
|
—
|
SECONDARY outcome
Timeframe: Pre-dose and EOI of Day 1 (Cycle 1)Population: PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)Population: PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=1 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
n=1 Participants
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=4 Participants
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=4 Participants
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=3 Participants
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=3 Participants
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=3 Participants
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
n=3 Participants
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=6 Participants
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Maximum Observed Concentration (Cmax) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1
|
429.00 Nanograms per milliliter
Geometric Coefficient of Variation NA
NA indicates that geometric coefficient of variation could not be calculated for a single participant.
|
1323.00 Nanograms per milliliter
Geometric Coefficient of Variation NA
NA indicates that geometric coefficient of variation could not be calculated for a single participant.
|
2956.77 Nanograms per milliliter
Geometric Coefficient of Variation 18.45
|
4548.10 Nanograms per milliliter
Geometric Coefficient of Variation 20.27
|
11876.46 Nanograms per milliliter
Geometric Coefficient of Variation 24.08
|
23050.05 Nanograms per milliliter
Geometric Coefficient of Variation 23.05
|
43774.18 Nanograms per milliliter
Geometric Coefficient of Variation 45.18
|
68128.02 Nanograms per milliliter
Geometric Coefficient of Variation 20.84
|
117385.57 Nanograms per milliliter
Geometric Coefficient of Variation 24.14
|
—
|
SECONDARY outcome
Timeframe: Pre-dose and EOI of Day 1 (Cycle 1)Population: PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1), Pre-dose and EOI of Day 1 (Cycle 2 and Cycle 4)Population: PK Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=1 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
n=1 Participants
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=4 Participants
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=4 Participants
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=4 Participants
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=3 Participants
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=4 Participants
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
n=3 Participants
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=6 Participants
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Trough Plasma Concentration (Ctrough) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1
Day 1, Cycle 1,n=0,1,4,2,1,3,3,2,6
|
—
|
NA Nanograms per milliliter
Geometric Coefficient of Variation NA
NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
|
381.95 Nanograms per milliliter
Geometric Coefficient of Variation 105.55
|
1331.11 Nanograms per milliliter
Geometric Coefficient of Variation 44.43
|
4307.00 Nanograms per milliliter
Geometric Coefficient of Variation NA
NA indicates that geometric coefficient of variation could not be calculated for a single participant.
|
3720.27 Nanograms per milliliter
Geometric Coefficient of Variation 113.71
|
11420.61 Nanograms per milliliter
Geometric Coefficient of Variation 35.70
|
28134.46 Nanograms per milliliter
Geometric Coefficient of Variation 35.97
|
2301.18 Nanograms per milliliter
Geometric Coefficient of Variation 75.69
|
—
|
|
Trough Plasma Concentration (Ctrough) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1
Day 1, Cycle 2,n=0,1,0,2,1,2,2,2,5
|
—
|
NA Nanograms per milliliter
Geometric Coefficient of Variation NA
NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
|
—
|
1672.18 Nanograms per milliliter
Geometric Coefficient of Variation 28.76
|
7259.00 Nanograms per milliliter
Geometric Coefficient of Variation NA
NA indicates that geometric coefficient of variation could not be calculated for a single participant.
|
9510.04 Nanograms per milliliter
Geometric Coefficient of Variation 104.56
|
12791.83 Nanograms per milliliter
Geometric Coefficient of Variation 46.82
|
12719.77 Nanograms per milliliter
Geometric Coefficient of Variation 6.21
|
2643.94 Nanograms per milliliter
Geometric Coefficient of Variation 123.56
|
—
|
SECONDARY outcome
Timeframe: Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 4)Population: PK Part 1 Population.Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=8 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Ctrough of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg
Day 1, Cycle 4,n=3
|
11121.73 Nanograms per milliliter
Geometric Coefficient of Variation 59.75
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Ctrough of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg
Day 1, Cycle 1,n=8
|
3726.78 Nanograms per milliliter
Geometric Coefficient of Variation 49.92
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Ctrough of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1: GSK2857916 2.50 mg/kg
Day 1, Cycle 2,n=4
|
11352.94 Nanograms per milliliter
Geometric Coefficient of Variation 268.64
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)Population: PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
n=1 Participants
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=4 Participants
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=3 Participants
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=3 Participants
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=2 Participants
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=1 Participants
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=4 Participants
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Terminal Half-life (t1/2) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1
|
—
|
126.18 Hours
Geometric Coefficient of Variation NA
NA indicates that geometric coefficient of variation could not be calculated for a single participant.
|
188.20 Hours
Geometric Coefficient of Variation 37.41
|
117.82 Hours
Geometric Coefficient of Variation 76.00
|
198.48 Hours
Geometric Coefficient of Variation 50.42
|
264.93 Hours
Geometric Coefficient of Variation 46.73
|
308.39 Hours
Geometric Coefficient of Variation NA
NA indicates that geometric coefficient of variation could not be calculated for a single participant.
|
—
|
103.74 Hours
Geometric Coefficient of Variation 17.29
|
—
|
SECONDARY outcome
Timeframe: Pre-dose and EOI of Day 1 (Cycle 1)Population: PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)Population: PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
n=1 Participants
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=4 Participants
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=3 Participants
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=3 Participants
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=2 Participants
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=1 Participants
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=4 Participants
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Volume of Distribution at Steady State (Vss) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1
|
—
|
5239 Milliliter
Geometric Coefficient of Variation NA
NA indicates that geometric coefficient of variation could not be calculated for a single participant.
|
2900 Milliliter
Geometric Coefficient of Variation 29.04
|
4286 Milliliter
Geometric Coefficient of Variation 31.29
|
4388 Milliliter
Geometric Coefficient of Variation 21.99
|
3224 Milliliter
Geometric Coefficient of Variation 22.37
|
5156 Milliliter
Geometric Coefficient of Variation NA
NA indicates that geometric coefficient of variation could not be calculated for a single participant.
|
—
|
5215 Milliliter
Geometric Coefficient of Variation 19.41
|
—
|
SECONDARY outcome
Timeframe: Pre-dose and EOI of Day 1 (Cycle 1)Population: PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)Population: PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. Median and full range of Tmax have been presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=1 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
n=1 Participants
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=4 Participants
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=4 Participants
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=3 Participants
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=3 Participants
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=3 Participants
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
n=3 Participants
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=6 Participants
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Time to Reach Maximum Observed Concentration (Tmax) of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM - Part 1
|
2.080 Hours
Interval 2.08 to 2.08
|
4.080 Hours
Interval 4.08 to 4.08
|
1.185 Hours
Interval 1.0 to 2.0
|
3.085 Hours
Interval 2.0 to 8.78
|
1.000 Hours
Interval 1.0 to 4.0
|
2.050 Hours
Interval 2.0 to 2.08
|
1.000 Hours
Interval 0.5 to 24.0
|
6.920 Hours
Interval 2.02 to 8.78
|
1.560 Hours
Interval 0.95 to 2.07
|
—
|
SECONDARY outcome
Timeframe: Pre-dose and EOI of Day 1 (Cycle 1)Population: PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods. Median and full range of Tmax have been presented.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 4)Population: PK Part 2 MM Population comprised of Part 2 MM participants of All Treated Population who had atleast 1 non-missing (NQ) PK assessment. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=35 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Ctrough of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM-Part 2
Day 1, Cycle 1,n=28
|
3486.49 Nanograms per milliliter
Geometric Coefficient of Variation 85.71
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Ctrough of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM-Part 2
Day 1, Cycle 2,n=18
|
5799.89 Nanograms per milliliter
Geometric Coefficient of Variation 66.52
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Ctrough of GSK2857916 Following IV Dose in Participants With Relapsed/Refractory MM-Part 2
Day 1, Cycle 4,n=12
|
6184.46 Nanograms per milliliter
Geometric Coefficient of Variation 103.79
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 3)Population: Part 2 NHL Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Blood samples were collected at designated timepoints. PK parameters of GSK2857916 were calculated using non-compartmental methods.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=5 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Ctrough of GSK2857916 Following IV Dose in Participants With NHL-Part 2
Cycle 1 Day 1, n=5
|
0.0 Nanograms per milliliter
Standard Deviation 0.00
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Ctrough of GSK2857916 Following IV Dose in Participants With NHL-Part 2
Cycle 2 Day 1, n=4
|
3761.8 Nanograms per milliliter
Standard Deviation 2225.57
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Ctrough of GSK2857916 Following IV Dose in Participants With NHL-Part 2
Cycle 3 Day 1, n=1
|
8401.0 Nanograms per milliliter
Standard Deviation NA
NA indicates that standard deviation could not be calculated for a single participant.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)Population: PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.
Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=1 Participants
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=4 Participants
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=3 Participants
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=3 Participants
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=3 Participants
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
n=3 Participants
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=6 Participants
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
AUC(0-tlast) of Cys Monomethyl Auristatin F (Cys-mcMMAF) Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1
|
—
|
—
|
1157.46 Hours*picogram per milliliter
Geometric Coefficient of Variation NA
NA indicates that geometric coefficient of variation could not be calculated for a single participant.
|
1623.87 Hours*picogram per milliliter
Geometric Coefficient of Variation 41.43
|
14681.62 Hours*picogram per milliliter
Geometric Coefficient of Variation 91.88
|
20787.48 Hours*picogram per milliliter
Geometric Coefficient of Variation 209.27
|
72608.00 Hours*picogram per milliliter
Geometric Coefficient of Variation 17.60
|
119177.30 Hours*picogram per milliliter
Geometric Coefficient of Variation 35.77
|
181147.61 Hours*picogram per milliliter
Geometric Coefficient of Variation 94.32
|
—
|
SECONDARY outcome
Timeframe: Pre-dose and EOI of Day 1 (Cycle 1)Population: PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.
Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)Population: PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.
Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that geometric coefficient of variation could not be calculated for a single participant.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=1 Participants
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=4 Participants
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=3 Participants
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=3 Participants
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=3 Participants
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
n=3 Participants
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=6 Participants
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Cmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1
|
—
|
—
|
51.50 Picograms per milliliter
Geometric Coefficient of Variation NA
NA indicates that geometric coefficient of variation could not be calculated for a single participant.
|
91.49 Picograms per milliliter
Geometric Coefficient of Variation 31.76
|
260.62 Picograms per milliliter
Geometric Coefficient of Variation 15.70
|
488.29 Picograms per milliliter
Geometric Coefficient of Variation 38.51
|
1054.02 Picograms per milliliter
Geometric Coefficient of Variation 18.96
|
1199.86 Picograms per milliliter
Geometric Coefficient of Variation 35.11
|
2544.02 Picograms per milliliter
Geometric Coefficient of Variation 87.04
|
—
|
SECONDARY outcome
Timeframe: Pre-dose and EOI of Day 1 (Cycle 1)Population: PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.
Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1), Pre-dose and EOI of Day 1 (Cycle 2 and Cycle 4)Population: PK Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=1 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
n=1 Participants
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=4 Participants
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=4 Participants
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=4 Participants
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=3 Participants
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=4 Participants
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
n=3 Participants
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=6 Participants
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Ctrough of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1
Day 1, Cycle 1,n=0,1,4,2,1,3,3,2,6
|
—
|
NA Picograms per milliliter
Geometric Coefficient of Variation NA
NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
|
NA Picograms per milliliter
Geometric Coefficient of Variation NA
NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
|
NA Picograms per milliliter
Geometric Coefficient of Variation NA
NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
|
NA Picograms per milliliter
Geometric Coefficient of Variation NA
NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
|
NA Picograms per milliliter
Geometric Coefficient of Variation NA
NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
|
NA Picograms per milliliter
Geometric Coefficient of Variation NA
NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
|
NA Picograms per milliliter
Geometric Coefficient of Variation NA
NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
|
NA Picograms per milliliter
Geometric Coefficient of Variation NA
NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
|
—
|
|
Ctrough of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1
Day 1, Cycle 2,n=0,1,0,2,1,2,2,2,5
|
—
|
NA Picograms per milliliter
Geometric Coefficient of Variation NA
NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
|
—
|
NA Picograms per milliliter
Geometric Coefficient of Variation NA
NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
|
NA Picograms per milliliter
Geometric Coefficient of Variation NA
NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
|
NA Picograms per milliliter
Geometric Coefficient of Variation NA
NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
|
NA Picograms per milliliter
Geometric Coefficient of Variation NA
NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
|
NA Picograms per milliliter
Geometric Coefficient of Variation NA
NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
|
NA Picograms per milliliter
Geometric Coefficient of Variation NA
NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
|
—
|
SECONDARY outcome
Timeframe: Pre-dose and EOI of Day 1 (Cycle 1, Cycle 2 and Cycle 4)Population: PK Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=8 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Ctrough of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg
Day 1, Cycle 1,n=8
|
NA Picograms per milliliter
Geometric Coefficient of Variation NA
NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Ctrough of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg
Day 1, Cycle 2,n=4
|
NA Picograms per milliliter
Geometric Coefficient of Variation NA
NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Ctrough of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1: GSK2857916 2.50 mg/kg
Day 1, Cycle 4,n=3
|
NA Picograms per milliliter
Geometric Coefficient of Variation NA
NA indicates that the geometric mean and geometric coefficient of variation could not be calculated since the concentration was not quantifiable.
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Pre-dose, 30 minutes post-SOI, at EOI, 1, 3, 8 and 24 hours post-EOI of Day 1 (Cycle 1)Population: PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.
Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. Median and full range of Tmax have been presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=1 Participants
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=4 Participants
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=3 Participants
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=3 Participants
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=3 Participants
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
n=3 Participants
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=6 Participants
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Tmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With Relapsed/Refractory MM- Part 1
|
—
|
—
|
49.130 Hours
Interval 49.13 to 49.13
|
23.875 Hours
Interval 9.0 to 24.63
|
24.730 Hours
Interval 24.0 to 25.83
|
9.050 Hours
Interval 8.78 to 22.83
|
8.750 Hours
Interval 7.75 to 24.0
|
23.700 Hours
Interval 23.17 to 24.97
|
24.040 Hours
Interval 7.83 to 25.0
|
—
|
SECONDARY outcome
Timeframe: Pre-dose and EOI of Day 1 (Cycle 1)Population: PK Part 1 Population. Only those participants with data available at the specified data points were analyzed.
Blood samples were collected at designated timepoints. PK parameters of Cys-mcMMAF were calculated using non-compartmental methods. Median and full range of Tmax have been presented.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)Population: Part 1 Population
Serum samples were collected for the determination of anti-GSK2857916 antibodies (ADA) using a validated electrochemiluminescent (ECL) immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with at least one confirmed positive ADA at any time post-Baseline is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=1 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
n=1 Participants
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=4 Participants
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=4 Participants
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=4 Participants
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=3 Participants
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=4 Participants
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
n=8 Participants
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=3 Participants
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
n=6 Participants
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 1
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)Population: Part 2 MM Population. Only those participants with data available at the specified data points were analyzed.
Serum samples were collected for the determination of anti-GSK2857916 antibodies (ADA) using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with at least one confirmed positive ADA at any time post-Baseline is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=33 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 2 (MM)
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)Population: Part 2 NHL Population. Only those participants with data available at the specified data points were analyzed.
Serum samples were collected for the determination of anti-GSK2857916 antibodies (ADA) using a validated ECLimmunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with at least one confirmed positive ADA at any time post-Baseline is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=5 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody Result- Part 2 (NHL)
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline, Day 1 (Cycle 2, 3, 4, 6, 9, 12, 16), End of study (within 30 days [+ 7 days of last treatment or prior to the start of new anti-cancer treatment], whichever is earlier) (1 cycle=21 days)Population: Part 1 Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Serum samples were collected for the determination of ADA using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive (pos) samples were titrated to obtain the titers of antibodies. The number of participants with screening, confirming and negative (neg) conclusive ADA results at Baseline and different timepoints is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=1 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
n=1 Participants
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=4 Participants
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=4 Participants
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=4 Participants
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=3 Participants
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=4 Participants
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
n=8 Participants
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=3 Participants
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
n=6 Participants
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Baseline,screening,pos, n=1,1,4,4,4,3,4,7,2,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
End of study,neg,conclusive,n=1,1,4,4,4,3,3,6,1,5
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Baseline,screening,neg, n=1,1,4,4,4,3,4,7,2,6
|
1 Participants
|
1 Participants
|
4 Participants
|
4 Participants
|
4 Participants
|
3 Participants
|
4 Participants
|
7 Participants
|
2 Participants
|
6 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Baseline,neg,conclusive,n=1,1,4,4,4,3,4,7,2,6
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
6 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Cycle 2 Day 1,screening,pos, n=0,1,4,2,2,3,3,8,3,5
|
—
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Cycle 2 Day 1,screening,neg, n=0,1,4,2,2,3,3,8,3,5
|
—
|
1 Participants
|
4 Participants
|
2 Participants
|
2 Participants
|
3 Participants
|
3 Participants
|
8 Participants
|
3 Participants
|
5 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Cycle 2 Day 1,neg,conclusive,n=0,1,4,2,2,3,3,8,3,5
|
—
|
1 Participants
|
3 Participants
|
2 Participants
|
2 Participants
|
3 Participants
|
3 Participants
|
8 Participants
|
2 Participants
|
5 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Cycle 3 Day 1,screening,pos, n=0,1,0,2,2,1,2,4,3,6
|
—
|
0 Participants
|
—
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Cycle 3 Day 1,screening,neg, n=0,1,0,2,2,1,2,4,3,6
|
—
|
1 Participants
|
—
|
2 Participants
|
2 Participants
|
1 Participants
|
2 Participants
|
4 Participants
|
3 Participants
|
6 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Cycle 3 Day 1,neg,conclusive,n=0,1,0,2,2,1,2,4,3,6
|
—
|
1 Participants
|
—
|
2 Participants
|
2 Participants
|
1 Participants
|
2 Participants
|
2 Participants
|
0 Participants
|
4 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Cycle 4 Day 1,screening,neg, n=0,0,0,0,0,0,0,0,0,1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
1 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Cycle 4 Day 1,neg,conclusive,n=0,0,0,0,0,0,0,0,0,1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Cycle 6 Day 1,screening,pos, n=0,0,0,1,1,1,2,3,3,3
|
—
|
—
|
—
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Cycle 6 Day 1,screening,neg, n=0,0,0,1,1,1,2,3,3,3
|
—
|
—
|
—
|
1 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
3 Participants
|
2 Participants
|
3 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Cycle 6 Day 1,neg,conclusive,n=0,0,0,1,1,1,2,3,3,3
|
—
|
—
|
—
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Cycle 9 Day 1,screening,pos, n=0,0,0,1,0,0,1,1,2,2
|
—
|
—
|
—
|
0 Participants
|
—
|
—
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Cycle 9 Day 1,screening,neg, n=0,0,0,1,0,0,1,1,2,2
|
—
|
—
|
—
|
1 Participants
|
—
|
—
|
1 Participants
|
1 Participants
|
2 Participants
|
2 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Cycle 9 Day 1,neg,conclusive,n=0,0,0,1,0,0,1,1,2,2
|
—
|
—
|
—
|
0 Participants
|
—
|
—
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Cycle 12 Day 1,screening,pos,n=0,0,0,1,0,0,1,1,1,3
|
—
|
—
|
—
|
0 Participants
|
—
|
—
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Cycle 12 Day 1,screening,neg,n=0,0,0,1,0,0,1,1,1,3
|
—
|
—
|
—
|
1 Participants
|
—
|
—
|
1 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Cycle 12 Day1,neg,conclusive,n=0,0,0,1,0,0,1,1,1,3
|
—
|
—
|
—
|
0 Participants
|
—
|
—
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Cycle 16 Day 1,screening,pos,n=0,0,0,0,0,0,1,1,1,2
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Cycle 16 Day 1,screening,neg,n=0,0,0,0,0,0,1,1,1,2
|
—
|
—
|
—
|
—
|
—
|
—
|
1 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Cycle 16 Day1,neg,conclusive,n=0,0,0,0,0,0,1,1,1,2
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
End of study,screening,pos,n=1,1,4,4,4,3,3,6,1,5
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
End of study,screening,neg,n=1,1,4,4,4,3,3,6,1,5
|
1 Participants
|
1 Participants
|
4 Participants
|
3 Participants
|
4 Participants
|
3 Participants
|
3 Participants
|
6 Participants
|
1 Participants
|
5 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
End of study,confirming,pos,n=0,0,0,1,0,0,0,0,0,0
|
—
|
—
|
—
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Cycle 4 Day 1,screening,pos, n=0,0,0,0,0,0,0,0,0,1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Cycle 6 Day 1,confirming,pos,n=0,0,0,0,0,0,0,0,1,0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Cycle 6 Day 1,confirming,neg,n=0,0,0,0,0,0,0,0,1,0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
1 Participants
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Cycle 12 Day1,confirming,pos,n=0,0,0,0,0,0,0,0,0,1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
Cycle 12 Day1,confirming,neg,n=0,0,0,0,0,0,0,0,0,1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
1 Participants
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 1
End of study,confirming,neg,n=0,0,0,1,0,0,0,0,0,0
|
—
|
—
|
—
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline, Day 1 (Cycle 2, 3, 6, 7, 9, 11, 12, 16), End of study (within 30 days [+ 7 days of last treatment or prior to the start of new anti-cancer treatment], whichever is earlier) (1 cycle=21 days)Population: Part 2 MM Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Serum samples were collected for the determination of ADA using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with screening, confirming and negative conclusive ADA results at Baseline and different timepoints is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=35 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Baseline, screening, positive, n=30
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Baseline, confirming, positive, n=2
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 2, Day 1, screening, positive, n=31
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 6, Day 1, screening, positive, n=17
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 16, Day 1, screening, negative, n=8
|
8 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 16, Day 1, negative, conclusive, n=8
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
End of study, screening, positive, n=21
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Baseline, screening, negative n=30
|
28 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Baseline, confirming, negative, n=2
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Baseline, negative, conclusive, n=30
|
21 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 2, Day 1, screening, negative, n=31
|
28 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 2, Day 1, confirming, positive, n=3
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 2, Day 1, confirming, negative, n=3
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 2, Day 1, negative, conclusive, n=31
|
27 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 3, Day 1, screening, positive, n=23
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 3, Day 1, screening, negative, n=23
|
23 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 3, Day 1, negative, conclusive, n=23
|
14 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 6, Day 1, screening, negative, n=17
|
13 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 6, Day 1, confirming, positive, n=4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 6, Day 1, confirming, negative, n=4
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 6, Day 1, negative, conclusive, n=17
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 7, Day 1, screening, positive, n=1
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 7, Day 1, screening, negative, n=1
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 7, Day 1, negative, conclusive, n=1
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 9, Day 1, screening, positive, n=16
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 9, Day 1, screening, negative, n=16
|
14 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 9, Day 1, confirming, positive, n=2
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 9, Day 1, confirming, negative, n=2
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 9, Day 1, negative, conclusive, n=16
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 11, Day 1, screening, positive, n=1
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 11, Day 1, screening, negative, n=1
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 11, Day 1, negative, conclusive, n=1
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 12, Day 1, screening, positive, n=8
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 12, Day 1, screening, negative, n=8
|
8 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 12, Day 1, negative, conclusive, n=8
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
Cycle 16, Day 1, screening, positive, n=8
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
End of study, screening, negative, n=21
|
20 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
End of study, confirming, positive, n=1
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
End of study, confirming, negative, n=1
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time- Part 2 (MM)
End of study, negative, conclusive, n=21
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline, Day 1 (Cycle 2, 3), End of study (within 30 days [+ 7 days of last treatment or prior to the start of new anti-cancer treatment], whichever is earlier) (1 cycle=21 days)Population: Part 2 NHL Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).
Serum samples were collected for the determination of ADA using a validated ECL immunoassay. The assay involved screening, confirmation and titration steps. If serum samples contained ADA, they were further analyzed for the specificity of antibodies by a confirmation assay. Confirmed positive samples were titrated to obtain the titers of antibodies. The number of participants with screening, confirming and negative conclusive ADA results at Baseline and different timepoints is presented.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=5 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time - Part 2 (NHL)
Baseline, negative, conclusive, n=5
|
5 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time - Part 2 (NHL)
Cycle 2, Day 1, screening, positive, n=4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time - Part 2 (NHL)
Cycle 2, Day 1, screening, negative, n=4
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time - Part 2 (NHL)
Baseline, screening, positive, n=5
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time - Part 2 (NHL)
Baseline, screening, negative n=5
|
5 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time - Part 2 (NHL)
Cycle 2, Day 1, negative, conclusive, n=4
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time - Part 2 (NHL)
Cycle 3, Day 1, screening, positive, n=2
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time - Part 2 (NHL)
Cycle 3, Day 1, screening, negative, n=2
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time - Part 2 (NHL)
Cycle 3, Day 1, confirming, positive, n=1
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time - Part 2 (NHL)
Cycle 3, Day 1, confirming, negative, n=1
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time - Part 2 (NHL)
Cycle 3, Day 1, negative, conclusive, n=2
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time - Part 2 (NHL)
End of study, screening, positive, n=4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time - Part 2 (NHL)
End of study, screening, negative, n=4
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Number of Participants With Antibodies to GSK2857916 in Serum Over Time - Part 2 (NHL)
End of study, negative, conclusive, n=4
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 21.6 months)Population: Part 1 Population
ORR was determined by the investigator according to international myeloma working group uniform response criteria for MM (IMWG 2011). ORR was calculated as the number of participants with best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) and partial response (PR).
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=1 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
n=1 Participants
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=4 Participants
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=4 Participants
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=4 Participants
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=3 Participants
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=4 Participants
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
n=8 Participants
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=3 Participants
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
n=6 Participants
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Response Rate (ORR)- Part 1
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
3 Participants
|
3 Participants
|
SECONDARY outcome
Timeframe: From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 24.2 months)Population: Part 2 MM Population
ORR was determined by the investigator according to IMWG 2011 uniform response criteria for MM. ORR was calculated as the number of participants with best overall response of sCR, CR, VGPR and PR.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=35 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
ORR-Part 2 (MM)
|
21 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 7.2 months)Population: Part 2 NHL Population
Overall Response Rate in NHL population was determined by the investigator according to Revised Response Criteria for Malignant Lymphoma. ORR was calculated as the number of participants with confirmed complete remission (CR) or partial remission (PR). Complete remission was defined as disappearance of all evidence of disease and partial remission was defined as regression of measurable disease and no new sites.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=6 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
ORR-Part 2 (NHL)
|
0 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 21.6 months)Population: Part 1 Population
CBR was calculated as the number of participants with best overall response of sCR, CR, VGPR, PR and minimal response (MR).
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=1 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
n=1 Participants
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=4 Participants
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=4 Participants
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=4 Participants
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=3 Participants
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=4 Participants
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
n=8 Participants
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=3 Participants
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
n=6 Participants
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Clinical Benefit Rate (CBR)- Part 1
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
2 Participants
|
3 Participants
|
5 Participants
|
SECONDARY outcome
Timeframe: From the Start of Treatment (at First Dose) up to the earlier of disease progression or the start of new anti-cancer therapy (maximum duration of follow-up is 24.2 months)Population: Part 2 MM Population. Data is presented only for Part 2 MM Population; since this analysis was not planned for Part 2 NHL Population.
CBR was calculated as the number of participants with best overall response of sCR, CR, VGPR, PR and MR.
Outcome measures
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=35 Participants
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|
|
CBR- Part 2
|
21 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
Adverse Events
Part 1: GSK2857916 0.03 mg/kg
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
Part 1: GSK2857916 0.06 mg/kg
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
Part 1: GSK2857916 0.12 mg/kg
Serious events: 1 serious events
Other events: 4 other events
Deaths: 0 deaths
Part 1: GSK2857916 0.24 mg/kg
Serious events: 1 serious events
Other events: 4 other events
Deaths: 0 deaths
Part 1: GSK2857916 0.48 mg/kg
Serious events: 1 serious events
Other events: 3 other events
Deaths: 0 deaths
Part 1: GSK2857916 0.96 mg/kg
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
Part 1: GSK2857916 1.92 mg/kg
Serious events: 2 serious events
Other events: 4 other events
Deaths: 0 deaths
Part 1: GSK2857916 2.50 mg/kg
Serious events: 4 serious events
Other events: 8 other events
Deaths: 1 deaths
Part 1: GSK2857916 3.40 mg/kg
Serious events: 1 serious events
Other events: 3 other events
Deaths: 0 deaths
Part 1: GSK2857916 4.60 mg/kg
Serious events: 3 serious events
Other events: 6 other events
Deaths: 1 deaths
Part 2: GSK2857916 3.40 mg/kg (MM)
Serious events: 17 serious events
Other events: 35 other events
Deaths: 5 deaths
Part 2: GSK2857916 3.40 mg/kg (NHL)
Serious events: 3 serious events
Other events: 6 other events
Deaths: 3 deaths
Serious adverse events
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=1 participants at risk
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
n=1 participants at risk
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=4 participants at risk
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=4 participants at risk
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=4 participants at risk
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=3 participants at risk
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=4 participants at risk
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
n=8 participants at risk
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=3 participants at risk
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
n=6 participants at risk
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 2: GSK2857916 3.40 mg/kg (MM)
n=35 participants at risk
Participants with multiple myeloma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle=21 days).
|
Part 2: GSK2857916 3.40 mg/kg (NHL)
n=6 participants at risk
Participants with non-hodgkin's lymphoma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 36 cycles (1 cycle=21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Respiratory, thoracic and mediastinal disorders
Pharyngeal haemorrhage
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Adenovirus infection
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
2.9%
1/35 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Appendicitis
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
2.9%
1/35 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
2.9%
1/35 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
2.9%
1/35 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Babesiosis
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
2.9%
1/35 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Bacteraemia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
2.9%
1/35 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Cholecystitis infective
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
2.9%
1/35 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Vascular disorders
Deep vein thrombosis
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Nervous system disorders
Encephalopathy
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
2.9%
1/35 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
2.9%
1/35 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
2.9%
1/35 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Gastroenteritis salmonella
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
2.9%
1/35 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
2.9%
1/35 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Nervous system disorders
Haemorrhage intracranial
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
2.9%
1/35 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Blood and lymphatic system disorders
Hyperviscosity syndrome
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Vascular disorders
Hypotension
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Influenza
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
2.9%
1/35 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Injury, poisoning and procedural complications
Infusion related reaction
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
5.7%
2/35 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Eye disorders
Limbal stem cell deficiency
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Lower respiratory tract infection
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
2.9%
1/35 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma in situ
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Blood and lymphatic system disorders
Neutropenia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
General disorders
Pain
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Cardiac disorders
Pericardial effusion
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
2.9%
1/35 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
14.3%
5/35 • Number of events 5 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Pneumonia haemophilus
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
2.9%
1/35 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
General disorders
Pyrexia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
2.9%
1/35 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Respiratory tract infection
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
2.9%
1/35 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Eye disorders
Retinal detachment
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
2.9%
1/35 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Salmonellosis
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
2.9%
1/35 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Nervous system disorders
Spinal cord compression
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Infection
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Musculoskeletal and connective tissue disorders
Pathological fracture
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
Other adverse events
| Measure |
Part 1: GSK2857916 0.03 mg/kg
n=1 participants at risk
Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.06 mg/kg
n=1 participants at risk
Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.12 mg/kg
n=4 participants at risk
Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.24 mg/kg
n=4 participants at risk
Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.48 mg/kg
n=4 participants at risk
Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 0.96 mg/kg
n=3 participants at risk
Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 1.92 mg/kg
n=4 participants at risk
Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 2.50 mg/kg
n=8 participants at risk
Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 3.40 mg/kg
n=3 participants at risk
Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 1: GSK2857916 4.60 mg/kg
n=6 participants at risk
Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).
|
Part 2: GSK2857916 3.40 mg/kg (MM)
n=35 participants at risk
Participants with multiple myeloma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle=21 days).
|
Part 2: GSK2857916 3.40 mg/kg (NHL)
n=6 participants at risk
Participants with non-hodgkin's lymphoma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 36 cycles (1 cycle=21 days).
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
66.7%
2/3 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
66.7%
4/6 • Number of events 5 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
37.1%
13/35 • Number of events 17 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
General disorders
Asthenia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
5.7%
2/35 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
5.7%
2/35 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Skin and subcutaneous tissue disorders
Acne
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
20.0%
7/35 • Number of events 8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Renal and urinary disorders
Albuminuria
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Alpha haemolytic streptococcal infection
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
100.0%
1/1 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
66.7%
2/3 • Number of events 4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
37.5%
3/8 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
50.0%
3/6 • Number of events 4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
28.6%
10/35 • Number of events 12 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Gastrointestinal disorders
Angina bullosa haemorrhagica
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
50.0%
2/4 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
11.4%
4/35 • Number of events 5 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Cardiac disorders
Atrial flutter
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Babesiosis
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
2/8 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
20.0%
7/35 • Number of events 7 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Investigations
Blood alkaline phosphatase increased
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
14.3%
5/35 • Number of events 7 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Investigations
Blood creatine phosphokinase increased
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
2/8 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
2/6 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
8.6%
3/35 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Investigations
Blood creatinine increased
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
5.7%
2/35 • Number of events 4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Investigations
Blood lactate dehydrogenase increased
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
2/6 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Eye disorders
Borderline glaucoma
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Cardiac disorders
Bradycardia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Bronchitis
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Cardiac disorders
Bundle branch block left
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Cardiac disorders
Bundle branch block right
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
General disorders
Catheter site discharge
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
General disorders
Chest discomfort
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
General disorders
Chills
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
50.0%
2/4 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
66.7%
2/3 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.7%
9/35 • Number of events 10 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Conjunctivitis
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
5.7%
2/35 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Conjunctivitis viral
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
20.0%
7/35 • Number of events 8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
14.3%
5/35 • Number of events 5 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Eye disorders
Corneal deposits
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Eye disorders
Corneal disorder
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Eye disorders
Corneal irritation
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Eye disorders
Corneal oedema
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Eye disorders
Corneal opacity
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
50.0%
2/4 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
2/8 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
66.7%
2/3 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
40.0%
14/35 • Number of events 16 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Endocrine disorders
Cushingoid
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
2/8 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
14.3%
5/35 • Number of events 6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Skin and subcutaneous tissue disorders
Decubitus ulcer
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
5.7%
2/35 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Psychiatric disorders
Depression
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
100.0%
1/1 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
28.6%
10/35 • Number of events 11 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Eye disorders
Diplopia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Nervous system disorders
Disturbance in attention
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Diverticulitis
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
5.7%
2/35 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
5.7%
2/35 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Eye disorders
Dry eye
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
50.0%
2/4 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
66.7%
2/3 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
37.1%
13/35 • Number of events 18 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Gastrointestinal disorders
Dry mouth
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Nervous system disorders
Taste disorder
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
8.6%
3/35 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
17.1%
6/35 • Number of events 6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Vascular disorders
Embolism
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
2/6 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
8.6%
3/35 • Number of events 4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Eye disorders
Eye pain
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
11.4%
4/35 • Number of events 4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Eye disorders
Eye pruritus
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Nervous system disorders
Facial nerve disorder
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
General disorders
Facial pain
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
General disorders
Fatigue
|
100.0%
1/1 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
50.0%
2/4 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
66.7%
2/3 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
37.5%
3/8 • Number of events 4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
66.7%
2/3 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
66.7%
4/6 • Number of events 4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
22.9%
8/35 • Number of events 9 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Vascular disorders
Flushing
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Eye disorders
Foreign body sensation in eyes
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
General disorders
Gait disturbance
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Investigations
Gamma-glutamyltransferase increased
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
20.0%
7/35 • Number of events 11 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
5.7%
2/35 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Gastrointestinal disorders
Gingival bleeding
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
5.7%
2/35 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Nervous system disorders
Headache
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
2/6 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
14.3%
5/35 • Number of events 5 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Injury, poisoning and procedural complications
Humerus fracture
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
50.0%
2/4 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
50.0%
2/4 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
8.6%
3/35 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Metabolism and nutrition disorders
Hypercreatininaemia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
11.4%
4/35 • Number of events 10 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Vascular disorders
Hypertension
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
8.6%
3/35 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Metabolism and nutrition disorders
Hyperuricaemia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
100.0%
1/1 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Nervous system disorders
Hypoaesthesia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Gastrointestinal disorders
Hypoaesthesia oral
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
11.4%
4/35 • Number of events 5 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
2/6 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Metabolism and nutrition disorders
Hypophagia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Metabolism and nutrition disorders
Hypophosphataemia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Vascular disorders
Hypotension
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Endocrine disorders
Hypothyroidism
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Blood and lymphatic system disorders
Increased tendency to bruise
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Influenza
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
General disorders
Influenza like illness
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Injury, poisoning and procedural complications
Infusion related reaction
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
5.7%
2/35 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
8.6%
3/35 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Investigations
Intraocular pressure increased
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
11.4%
4/35 • Number of events 4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Eye disorders
Keratitis
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
8.6%
3/35 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Eye disorders
Keratopathy
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
8.6%
3/35 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Injury, poisoning and procedural complications
Skin laceration
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Eye disorders
Lacrimation increased
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
11.4%
4/35 • Number of events 6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Gastrointestinal disorders
Lip pain
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Lower respiratory tract infection bacterial
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Investigations
Lymphocyte count decreased
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
8.6%
3/35 • Number of events 8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Blood and lymphatic system disorders
Lymphopenia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
General disorders
Malaise
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Renal and urinary disorders
Micturition urgency
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
5.7%
2/35 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Nervous system disorders
Migraine
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
8.6%
3/35 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
2/8 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
11.4%
4/35 • Number of events 4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Eye disorders
Photopsia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal stiffness
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
2/6 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
5.7%
2/35 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Nasopharyngitis
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
8.6%
3/35 • Number of events 4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
50.0%
2/4 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
50.0%
2/4 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
75.0%
3/4 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
37.5%
3/8 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
66.7%
2/3 • Number of events 5 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
66.7%
4/6 • Number of events 4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
31.4%
11/35 • Number of events 15 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
2/8 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Nervous system disorders
Neuropathy peripheral
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Blood and lymphatic system disorders
Neutropenia
|
100.0%
1/1 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
100.0%
1/1 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
5.7%
2/35 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Investigations
Neutrophil count decreased
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
8.6%
3/35 • Number of events 5 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Skin and subcutaneous tissue disorders
Night sweats
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Renal and urinary disorders
Nocturia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Eye disorders
Ocular hypertension
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Eye disorders
Ocular toxicity
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
5.7%
2/35 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
General disorders
Oedema peripheral
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
8.6%
3/35 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Eye disorders
Optic disc haemorrhage
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Oral herpes
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
8.6%
3/35 • Number of events 4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Musculoskeletal and connective tissue disorders
Osteonecrosis of jaw
|
100.0%
1/1 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
General disorders
Pain
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
11.4%
4/35 • Number of events 4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Skin and subcutaneous tissue disorders
Petechiae
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Eye disorders
Photophobia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
2/6 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
28.6%
10/35 • Number of events 11 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Investigations
Platelet count decreased
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
37.1%
13/35 • Number of events 30 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
11.4%
4/35 • Number of events 5 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Nervous system disorders
Presyncope
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Renal and urinary disorders
Proteinuria
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
5.7%
2/35 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
37.5%
3/8 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Eye disorders
Punctate keratitis
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
General disorders
Pyrexia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
50.0%
2/4 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
2/6 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.7%
9/35 • Number of events 13 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
11.4%
4/35 • Number of events 5 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
8.6%
3/35 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Nervous system disorders
Restless legs syndrome
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Rhinitis
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinitis allergic
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Injury, poisoning and procedural complications
Rib fracture
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
5.7%
2/35 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Cardiac disorders
Sinus tachycardia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Sinusitis
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
14.3%
5/35 • Number of events 8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Skin and subcutaneous tissue disorders
Skin hypopigmentation
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Skin infection
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
5.7%
2/35 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Injury, poisoning and procedural complications
Spinal compression fracture
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Injury, poisoning and procedural complications
Spinal cord injury thoracic
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Gastrointestinal disorders
Stomatitis
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Nervous system disorders
Syncope
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Cardiac disorders
Tachycardia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Skin and subcutaneous tissue disorders
Telangiectasia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
100.0%
1/1 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
100.0%
1/1 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 7 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
66.7%
2/3 • Number of events 4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
83.3%
5/6 • Number of events 9 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.7%
9/35 • Number of events 18 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Tooth infection
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Gastrointestinal disorders
Toothache
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
5.7%
2/35 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.7%
9/35 • Number of events 12 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Respiratory, thoracic and mediastinal disorders
Upper-airway cough syndrome
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
11.4%
4/35 • Number of events 7 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Renal and urinary disorders
Urinary tract pain
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
12.5%
1/8 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Cardiac disorders
Ventricular extrasystoles
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Eye disorders
Vision blurred
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
75.0%
3/4 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
2/8 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
100.0%
3/3 • Number of events 11 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
66.7%
4/6 • Number of events 4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
51.4%
18/35 • Number of events 53 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
2/6 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Eye disorders
Visual impairment
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
50.0%
2/4 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
100.0%
1/1 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
1/3 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
33.3%
2/6 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
5.7%
2/35 • Number of events 3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Investigations
White blood cell count decreased
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
25.0%
1/4 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Investigations
Blood immunoglobulin G decreased
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Renal and urinary disorders
Pollakiuria
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Eye disorders
Periorbital swelling
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Metabolism and nutrition disorders
Hyperphosphataemia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Hepatobiliary disorders
Jaundice
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour pain
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/35 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
16.7%
1/6 • Number of events 1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/1 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/4 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/8 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/3 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
5.7%
2/35 • Number of events 2 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
0.00%
0/6 • SAEs & common (>=5%) non-SAEs were collected from start of study treatment until 23.5 months for Part 1, 35 months for Part 2 (MM) and 7.2 months for Part 2 (NHL)
SAEs and common (\>=5%) non-SAEs were reported by treatment for the Part 1 Population which comprised of all Part 1 participants (exclusively MM) who received at least one dose of GSK2857916; Part 2 MM and NHL Population which comprised of all Part 2 MM and NHL participants who received at least one dose of GSK2857916.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
- Publication restrictions are in place
Restriction type: OTHER